NCT ID,Asset,Title,Lead Sponsor,Acronym,Overall Status,Enrollment,Start Date,Conditions,Interventions,Primary Outcome(s),Secondary Outcome(s),Locations,Primary Completion Date,Study First Post Date,Last Update Post Date,Study Type,Phases
NCT01636492,Bitopertin,"Single Oral Ascending Dose Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO4917838 in Healthy Male Volunteers.",Hoffmann-La Roche,Unknown,COMPLETED,71,2005-11,Healthy Volunteer,"bitopertin, placebo",Safety: Incidence of adverse events,"Pharmacokinetics: Area under the concentration-time curve, Pharmacokinetics: Urine concentrations drug/metabolites",Christchurch - New Zealand,2006-08,2012-07-10,2016-11-02,INTERVENTIONAL,PHASE1
NCT05308472,Bitopertin,"(AURORA) A Randomized, Double-blind, Placebo-Controlled Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and Protoporphyrin IX (PPIX) Concentrations in Participants With Erythropoietic Protoporphyria (EPP)","Disc Medicine, Inc",Unknown,ACTIVE_NOT_RECRUITING,75,2022-10-31,Erythropoietic Protoporphyria,"DISC-1459, DISC-1459, Placebo, DISC-1459",Percent change from baseline in whole blood metal-free PPIX levels,"Total hours of sunlight exposure to skin on days with no pain from 1000 to 1800 hours (10:00am to 6:00pm), Daily sunlight exposure time (minutes) to first prodromal symptom (burning, tingling, itching, or stinging) associated with sunlight exposure between 1 hour post-sunrise and 1 hour pre-sunset, Pain intensity of phototoxic reactions according to a Likert scale (0-10), Incidence of treatment-emergent adverse events, Erythrocyte total PPIX concentrations, Plasma total PPIX concentrations, Whole blood total PPIX concentrations, Plasma bitopertin concentrations","Birmingham - United States, San Francisco - United States, Miami - United States, Boston - United States, New York - United States, Winston-Salem - United States, Philadelphia - United States, Galveston - United States, Seattle - United States",2024-02-20,2022-04-04,2024-04-15,INTERVENTIONAL,PHASE2
NCT01192880,Bitopertin,"A Phase III, Multi-Center, Randomized, 24 Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-Blind Treatment Period",Hoffmann-La Roche,Unknown,COMPLETED,625,2010-11,Schizophrenia,"Placebo, Bitopertin, Antipsychotics","Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Negative Symptom Factor Score at Week 24, Percentage of Participants with Adverse Events","Mean Change from Baseline in the Personal and Social Performance (PSP) Total Score at Week 24, Mean Change from Baseline in the PANSS Total Score at Week 24, Mean Change from Baseline in the PANSS Factor Scores at Week 24, Mean Change from Baseline in the PANSS Subscale Scores at Week 24, Percentage of Participants With Response, as Assessed by PANSS Negative Symptom Factor Score, Percentage of Participants with Response, as Assessed by CGI-I Overall and Negative Symptoms Rating Score, Percentage of Participants with Both At Least 20% Improvement from Baseline in the PANSS Negative Symptom Factor Score and with a CGI-I Negative Symptoms Rating of Either Much or Very Much Improvement, Mean Change from Baseline in the CGI-S Overall and Negative Symptoms Rating Score","Costa Mesa - United States, Escondido - United States, Granada Hills - United States, La Jolla - United States, Oceanside - United States, San Diego - United States, Torrance - United States, Lauderhill - United States, Miami - United States, Orange City - United States, Plantation - United States, Atlanta - United States, Indianapolis - United States, Glen Burnie - United States, Flowood - United States, Las Vegas - United States, Toms River - United States, Buffalo - United States, New York - United States, Rochester - United States, Durham - United States, Norristown - United States, Scranton - United States, Austin - United States, Irving - United States, Salt Lake City - United States, Kirkland - United States, Bourgas - Bulgaria, Kazanlak - Bulgaria, Novi Iskar - Bulgaria, Pazardzhik - Bulgaria, Plovdiv - Bulgaria, Radnevo - Bulgaria, Rousse - Bulgaria, Sofia - Bulgaria, Baoding - China, Beijing - China, Beijing - China, Beijing - China, Changsha - China, Chengdu - China, GuangzhouGuangdong - China, Hangzhou - China, Hangzhou - China, Kunming - China, Nanjing - China, Shanghai - China, Shanghai - China, Wuhan - China, Wuxi - China, Xi'an - China, Xi'an - China, Xi'an - China, Brno - Czech Republic, Liberec - Czech Republic, Melnik - Czech Republic, Plzen - Czech Republic, Praha 10 - Czech Republic, Praha 6 - Czech Republic, Praha 8 - Bohnice - Czech Republic, Sternberk - Czech Republic, Napoli - Italy, Brescia - Italy, Milano - Italy, Milano - Italy, Torino - Italy, Bari - Italy, Pisa - Italy, Padova - Italy, Chiba - Japan, Funabashi-shi - Japan, Gunma - Japan, Hiroshima-shi - Japan, Hokkaido - Japan, Kanzaki-gun - Japan, Kita-Ku - Japan, Kitakyushu-shi - Japan, Kochi-shi - Japan, Koshi-shi - Japan, Kumamoto-shi - Japan, Kurayoshi-shi - Japan, Nagoya-Shi - Japan, Omuta-shi - Japan, Sakai-shi - Japan, Sapporo-shi - Japan, Sapporo-shi - Japan, Sendai-shi - Japan, Shirakawa-shi - Japan, Tokyo - Japan, Tokyo - Japan, Toyama-shi - Japan, Toyoake-shi - Japan, Yokohama-shi - Japan, Yokohama-shi - Japan, Yokohama-shi - Japan, Kemerovo - Russian Federation, Lipetsk - Russian Federation, Moscow - Russian Federation, Moscow - Russian Federation, Sartatov - Russian Federation, St. Petersburg - Russian Federation, St. Petersburg - Russian Federation, Talagi - Russian Federation",2014-07,2010-09-01,2017-02-15,INTERVENTIONAL,PHASE3
NCT05883748,Bitopertin,"An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With Erythropoietic Protoporphyria (EPP)","Disc Medicine, Inc",Unknown,ENROLLING_BY_INVITATION,200,2023-08-31,Erythropoietic Protoporphyria,"DISC-1459, DISC-1459","Incidence of treatment-emergent adverse events, Incidence of clinically abnormal vital signs, Incidence of clinically abnormal physical exam, Incidence of abnormal laboratory test results, Assessment of Patient Health Questionnaire (PHQ-8), Assessment of C-SSRS","Change from baseline in daily daylight tolerance, as assessed by total hours spent in the sunlight without pain and average time to first prodromal syndrome in sunlight, Change from baseline in whole blood metal-free PPIX levels, Plasma Bitopertin Concentrations","Birmingham - United States, San Francisco - United States, Miami - United States, Boston - United States, New York - United States, Winston-Salem - United States, Philadelphia - United States, Galveston - United States, Seattle - United States, Camperdown - Australia, Parkville - Australia",2028-06,2023-06-01,2024-02-22,INTERVENTIONAL,"PHASE2, PHASE3"
NCT02019290,Bitopertin,"A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSE BITOPERTIN ON SINGLE DOSE PHARMACOKINETICS OF MIDAZOLAM IN HEALTHY VOLUNTEERS",Hoffmann-La Roche,Unknown,WITHDRAWN,0,2014-02-10,Healthy Volunteer,"Midazolam, bitopertin",Change in plasma area under the concentration-time curve (AUC) of midazolam after bitopertin administration,"Change in 1'-hydroxymidazolam plasma AUC after bitopertin administration, Incidence of adverse events",No locations listed,2014-03-31,2013-12-24,2017-10-25,INTERVENTIONAL,PHASE1
NCT05828108,Bitopertin,"A Phase I/II, Intra-Patient Dose-Escalation Study of the Selective GlyT1 Inhibitor, Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia.","National Heart, Lung, and Blood Institute (NHLBI)",Unknown,RECRUITING,30,2023-07-25,Steroid-refractory Diamond-Blackfan Anemia (DBA),Bitopertin,Rate of response,"Rate of relapse, Long-term safety of drug, Tolerability of drug, Safety of drug, Clonal evolution on bitopertin, Rate of overall survival, Health-related quality of life (HRQL)",Bethesda - United States,2029-05-01,2023-04-25,2024-04-10,INTERVENTIONAL,"PHASE1, PHASE2"
NCT03271541,Bitopertin,"A Phase II, Single Arm, Multicenter, Proof-of-Mechanism Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent Βeta-Thalassemia",Hoffmann-La Roche,Unknown,COMPLETED,12,2017-10-26,Beta-Thalassemia,Bitopertin,"Safety Outcome: Percentage of Participants with Adverse Events (AEs) - Part 1 only, Efficacy Outcome: Change in Total Hemoglobin (Hb) Level from Baseline to End of 16-Week Treatment Period in Part 1, Long-term Safety Outcome : Percentage of Participants with Adverse Events (AEs) - Part 2 only","Apparent Clearance of Bitopertin, Volume of Distribution of Bitopertin, Area Under the Concentration-Time Curve (AUC) of Bitopertin within a Dosing Interval, Minimum Observed Concentration (Cmin) of Bitopertin, Maximum Observed Concentration (Cmax) of Bitopertin, Apparent Elimination Half-Life of Bitopertin, Accumulation Ratio of Bitopertin, Change from Baseline in Absolute Reticulocyte Count, Change from Baseline in Serum Lactate Dehydrogenase Level, Change from Baseline in Serum Bilirubin Level, Change from Baseline in Absolute Red Blood Cell Count, Change in Total Hb Level from Baseline to the End of the Treatment Period in Part 2","Genova - Italy, Milano - Italy, Baabda - Lebanon, Bangkok Noi - Thailand",2018-06-29,2017-09-05,2018-10-05,INTERVENTIONAL,PHASE2
NCT01192906,Bitopertin,"A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.",Hoffmann-La Roche,Unknown,COMPLETED,624,2010-12,Schizophrenia,"Placebo, bitopertin [RO4917838], bitopertin [RO4917838]","Efficacy (PANSS negative symptoms factor score), Safety (incidence of adverse events)",No secondary outcomes listed,"Carson - United States, Oceanside - United States, San Diego - United States, San Diego - United States, Hartford - United States, Norwalk - United States, North Miami - United States, Atlanta - United States, Chicago - United States, Hoffman Estates - United States, Joliet - United States, Lake Charles - United States, Shreveport - United States, St. Louis - United States, Omahac - United States, Cedarhurst - United States, Jamaica - United States, Rochester - United States, Allentown - United States, Norristown - United States, Philadelphia - United States, Salvador - Brazil, Goiania - Brazil, Belo Horizonte - Brazil, Curitiba - Brazil, Rio de Janeiro - Brazil, Pelotas - Brazil, Porto Alegre - Brazil, Sao Paulo - Brazil, Sao Paulo - Brazil, Calgary - Canada, Medicine Hat - Canada, Vancouver - Canada, Victoria - Canada, Halifax - Canada, Burlington - Canada, Hamilton - Canada, Mississauga - Canada, Montreal - Canada, Montreal - Canada, Verdun - Canada, San Miguel - Chile, Santiago - Chile, Santiago - Chile, Santiago - Chile, Santiago - Chile, Santiago - Chile, Valdivia - Chile, Berlin - Germany, Bochum - Germany, Freiburg - Germany, Hamburg - Germany, Koeln - Germany, Muenchen - Germany, München - Germany, Nürnberg - Germany, Daugovpils - Latvia, Jelgava - Latvia, Liepaja - Latvia, Kaunas - Lithuania, Kaunas - Lithuania, Kaunas - Lithuania, Kaunas - Lithuania, Silute - Lithuania, Vilnius - Lithuania, Vilnius - Lithuania, Assen - Netherlands, Groningen - Netherlands, Groningen - Netherlands, Choroszcz - Poland, Kielce - Poland, Lublin - Poland, Lublin - Poland, Lublin - Poland, Piekary Slaskie - Poland, Skorzewo - Poland, Tuszyn - Poland, Warszawa - Poland, Bojnice - Slovakia, Bratislava - Slovakia, Bratislava - Slovakia, Rimavska Sobota - Slovakia, Svidnik - Slovakia, Oviedo - Spain, Barcelona - Spain, Barcelona - Spain, Barcelona - Spain, Madrid - Spain, Madrid - Spain, Salamanca - Spain, Zamora - Spain, Hualian Town - Taiwan, Kaohsiung - Taiwan, Taichung - Taiwan, Tainan County - Taiwan, Tainan - Taiwan, Taipei - Taiwan, Taipei - Taiwan, Ankara - Turkey, Diyarbakir - Turkey, Gaziantep - Turkey, Istanbul - Turkey, Istanbul - Turkey, Manisa - Turkey, Dnipropetrovsk - Ukraine, Donetsk - Ukraine, Glevakha Kyviv region - Ukraine, Kharkiv - Ukraine, Kyiv - Ukraine, Kyiv - Ukraine, Lviv - Ukraine, Odessa - Ukraine, Vinnytsya - Ukraine",2014-07,2010-09-01,2016-11-02,INTERVENTIONAL,PHASE3
NCT01234779,Bitopertin,"A Phase II, Multi-center, Randomized, 4-week, Double-blind, Parallel Group, Placebo and Active-controlled Trial of the Safety and Efficacy of RO4917838 vs. Placebo in Patients With an Acute Exacerbation of Schizophrenia",Hoffmann-La Roche,Unknown,COMPLETED,301,2011-02,Schizophrenia,"bitopertin [RO4917838], bitopertin [RO4917838], olanzapine, placebo","Change in Positive and Negative Syndrome Scale (PANSS) total score, Safety: Incidence adverse events","Clinical response, defined as at least 30% or 50% improvement from baseline PANSS total score, Change in symptomatology as measured by the PANSS factor and subscale scores, Global improvement as measured by the Clinical Global Impressions-Severity (CGI-S) scale, Global improvement as measured by the Clinical Global Impressions-Change (CGI-C) rating scale, Observable behavioural change as determined by the Nurses' Observation Scale For Inpatient Evaluation (NOSIE), Time to readiness for discharge from inpatient unit as assessed by the Readiness For Hospital Discharge Questionnaire (RDQ)","Little Rock - United States, Cerritos - United States, Oceanside - United States, Pico Rivera - United States, San Diego - United States, Lauderhill - United States, North Miami - United States, Atlanta - United States, Lake Charles - United States, Flowood - United States, St. Louis - United States, Willingboro - United States, Holliswood - United States, New York - United States, Cincinnati - United States, Philadelphia - United States, Charlesston - United States, Austin - United States, Irving - United States, Arad - Romania, Bucuresti - Romania, Bucuresti - Romania, Bucuresti - Romania, Foscani - Romania, Oradea - Romania, Targoviste - Romania, Gatchina - Russian Federation, Moscow - Russian Federation, Petrozavodsk - Russian Federation, St Petersburg - Russian Federation, St Petersburg - Russian Federation, St Petersburg - Russian Federation, St Petersburg - Russian Federation, St. Petersburg - Russian Federation, Talagi - Russian Federation, Bojnice - Slovakia, Bratislava - Slovakia, Liptovsky Mikulas - Slovakia, Michalovce - Slovakia, Dnipropetrovsk - Ukraine, Donetsk - Ukraine, Kherson,Vil. Stepanivka - Ukraine, Kyiv - Ukraine, Kyiv - Ukraine, Poltava - Ukraine, Vinnytsya - Ukraine",2012-09,2010-11-04,2016-11-02,INTERVENTIONAL,PHASE2
NCT01235559,Bitopertin,"Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.",Hoffmann-La Roche,Unknown,COMPLETED,604,2010-12,Schizophrenia,"Placebo, bitopertin [RO4917838] level 1, bitopertin [RO4917838] level 2","Positive symptoms factor score assessed by Positive and Negative Syndrome Scale (PANSS), Safety (incidence of adverse events)","Symptom domains of schizophrenia using Positive and Negative Syndrome Scale (PANSS), Disease improvement on Clinical Global Impression - Improvement (CGI-I) symptoms scale, Disease severity on Clinical Global Impression - Severity (CGI-S) symptoms scale, Safety (incidence of adverse events)","Costa Mesa - United States, Escondido - United States, Granada Hills - United States, La Jolla - United States, Oceanside - United States, San Diego - United States, Torrance - United States, Lauderhill - United States, Orange City - United States, Plantation - United States, Atlanta - United States, Indianapolis - United States, Flowood - United States, Las Vegas - United States, Buffalo - United States, New York - United States, Rochester - United States, Durham - United States, Scranton - United States, Austin - United States, Irving - United States, Salt Lake City - United States, Bourgas - Bulgaria, Kazanlak - Bulgaria, Novi Iskar - Bulgaria, Pazardzhik - Bulgaria, Plovdiv - Bulgaria, Radnevo - Bulgaria, Rousse - Bulgaria, Sofia - Bulgaria, Baoding - China, Beijing - China, Beijing - China, Beijing - China, Changsha - China, Chengdu - China, GuangzhouGuangdong - China, Hangzhou - China, Kunming - China, Nanjing - China, Shanghai - China, Shanghai - China, Wuhan - China, Wuxi - China, Xi'an - China, Xi'an - China, Brno - Czech Republic, Liberec - Czech Republic, Melnik - Czech Republic, Plzen - Czech Republic, Praha 10 - Czech Republic, Praha 6 - Czech Republic, Praha 8 - Bohnice - Czech Republic, Sternberk - Czech Republic, Napoli - Italy, Brescia - Italy, Milano - Italy, Milano - Italy, Torino - Italy, Bari - Italy, Pisa - Italy, Pisa - Italy, Padova - Italy, Chiba - Japan, Funabashi-shi - Japan, Gunma - Japan, Hiroshima-shi - Japan, Hokkaido - Japan, Kanzaki-gun - Japan, Kita-Ku - Japan, Kitakyushu-shi - Japan, Kochi-shi - Japan, Koshi-shi - Japan, Kumamoto-shi - Japan, Kurayoshi-shi - Japan, Nagoya-Shi - Japan, Omuta-shi - Japan, Sakai-shi - Japan, Sapporo-shi - Japan, Sapporo-shi - Japan, Sendai-shi - Japan, Shirakawa-shi - Japan, Tokyo - Japan, Tokyo - Japan, Toyama-shi - Japan, Toyoake-shi - Japan, Yokohama-shi - Japan, Yokohama-shi - Japan, Yokohama-shi - Japan, St. Petersburg - Russian Federation",2015-03,2010-11-05,2016-11-02,INTERVENTIONAL,PHASE3
NCT01235585,Bitopertin,"Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.",Hoffmann-La Roche,Unknown,COMPLETED,597,2010-12,Schizophrenia,"Placebo, bitopertin [RO4917838], bitopertin [RO4917838]","Positive symptoms factor score assessed by Positive and Negative Syndrome Scale (PANSS), Safety (incidence of adverse events)","Symptom domains of schizophrenia using Positive and Negative Syndrome Scale (PANSS), Disease improvement on Clinical Global Impression - Improvement (CGI-I) symptoms scale, Disease severity on Clinical Global Impression - Severity (CGI-S) symptoms scale, Safety (incidence of adverse events)","Carson - United States, Garden Grove - United States, Long Beach - United States, Long Beach - United States, Oceanside - United States, San Diego - United States, San Diego - United States, Hartford - United States, Norwalk - United States, North Miami - United States, Atlanta - United States, Chicago - United States, Hoffman Estates - United States, Joliet - United States, Lake Charles - United States, St. Louis - United States, St. Louis - United States, Omahac - United States, Cedarhurst - United States, Jamaica - United States, Rochester - United States, Allentown - United States, Norristown - United States, Philadelphia - United States, Bothell - United States, Salvador - Brazil, Goiania - Brazil, Belo Horizonte - Brazil, Curitiba - Brazil, Rio de Janeiro - Brazil, Pelotas - Brazil, Porto Alegre - Brazil, Itapira - Brazil, Sao Paulo - Brazil, Sao Paulo - Brazil, Calgary - Canada, Medicine Hat - Canada, Vancouver - Canada, Halifax - Canada, Burlington - Canada, Hamilton - Canada, Mississauga - Canada, Montreal - Canada, Montreal - Canada, Santiago - Chile, Santiago - Chile, Santiago - Chile, Santiago - Chile, Santiago - Chile, Santiago - Chile, Valdivia - Chile, Berlin - Germany, Bochum - Germany, Freiburg - Germany, Hamburg - Germany, Koeln - Germany, Muenchen - Germany, Muenchen - Germany, Nürnberg - Germany, Daugovpils - Latvia, Jelgava - Latvia, Liepaja - Latvia, Kaunas - Lithuania, Kaunas - Lithuania, Kaunas - Lithuania, Kaunas - Lithuania, Silute - Lithuania, Vilnius - Lithuania, Vilnius - Lithuania, Assen - Netherlands, Groningen - Netherlands, Groningen - Netherlands, Choroszcz - Poland, Kielce - Poland, Lublin - Poland, Lublin - Poland, Lublin - Poland, Piekary Slaskie - Poland, Skorzewo - Poland, Tuszyn - Poland, Warszawa - Poland, Bojnice - Slovakia, Bratislava - Slovakia, Bratislava - Slovakia, Rimavska Sobota - Slovakia, Svidnik - Slovakia, Trnava - Slovakia, Oviedo - Spain, Barcelona - Spain, Barcelona - Spain, Barcelona - Spain, Madrid - Spain, Madrid - Spain, Salamanca - Spain, Zamora - Spain, Hualian Town - Taiwan, Kaohsiung - Taiwan, Taichung - Taiwan, Tainan County - Taiwan, Tainan - Taiwan, Taipei - Taiwan, Taipei - Taiwan, Ankara - Turkey, Diyarbakir - Turkey, Gaziantep - Turkey, Istanbul - Turkey, Istanbul - Turkey, Istanbul - Turkey, Kocaeli - Turkey, Manisa - Turkey, Mersin - Turkey, Dnipropetrovsk - Ukraine, Donetsk - Ukraine, Glevakha Kyviv region - Ukraine, Kharkiv - Ukraine, Kyiv - Ukraine, Kyiv - Ukraine, Lviv - Ukraine, Odesa - Ukraine, Vinnytsya - Ukraine",2014-09,2010-11-05,2016-11-02,INTERVENTIONAL,PHASE3
NCT01674361,Bitopertin,"A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive Compulsive Disorder",Hoffmann-La Roche,Unknown,COMPLETED,99,2012-12-31,Obsessive-Compulsive Disorder,"Bitopertin, Placebo, SSRI",Change From Baseline in Total Score on Yale-Brown Obsessive Compulsive Scale (Y-BOCS) After 12 Weeks of Treatment,"Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score After 12 Weeks of Treatment, Percentage of Participants with Response as per Pre-defined Criteria Based on the Y-BOCS and CGI, Change From Baseline in Global Social Functioning Using Sheehan Disability Scale (SDS) Total Score After 12 Weeks of Treatment, Change From Baseline in Global Social Functioning Using SDS Domain Scores After 12 Weeks of Treatment, Change From Baseline in Obsessive Compulsive Inventory-Revised (OCI-R) Score After 12 Weeks of Treatment, Change From Baseline in Columbia Suicide Severity Rating Scale After 12 Weeks of Treatment, Change From Baseline in 36-Item Short-Form Health Survey (SF-36) - Mental Component Summary After 12 Weeks of Treatment, Change From Baseline in SF-36 - Physical Component Summary After 12 Weeks of Treatment, Change From Baseline in SF-36 - Domain Scores After 12 Weeks of Treatment, Area Under The Concentration-Time Curve of Bitopertin","Oceanside - United States, Stanford - United States, New Haven - United States, Leesburg - United States, Orange City - United States, Saint Petersburg - United States, Tampa - United States, Decatur - United States, Smyrna - United States, Chicago - United States, New Orleans - United States, Boston - United States, Boston - United States, Minneapolis - United States, Flowood - United States, Saint Louis - United States, New York - United States, New York - United States, Rochester - United States, Middleburg Heights - United States, Oklahoma City - United States, Norristown - United States, Providence - United States, Memphis - United States, Austin - United States, Kirkland - United States, Middleton - United States, Edmonton - Canada, Kelowna - Canada, Halifax - Canada, Kentville - Canada, Hamilton - Canada, Mississauga - Canada, Toronto - Canada",2015-04-30,2012-08-28,2017-08-02,INTERVENTIONAL,PHASE2
NCT06139055,GSBR-1290,"A 2-part, Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Comparative Bioavailability of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants","Gasherbrum Bio, Inc",Unknown,ACTIVE_NOT_RECRUITING,70,2023-10-02,Healthy Volunteers,"GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet)","Part 1: Analysis of Maximum Observed Plasma Concentration (Cmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate Pharmacokinetic (PK) Parameters, Part 1: Analysis of Time to Maximum Observed Plasma Concentration (Tmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters, Part 1: Analysis of Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters, Part 1: Analysis of Area Under the Plasma Concentration-time Curve From 0 to infinity (AUC0-inf) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters, Part 1: Analysis of Apparent Terminal Elimination Half-life (t1/2) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters, Part 1: Analysis of Total Apparent Body Clearance (CL/F) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters, Part 1: Analysis of Apparent Volume of Distribution (Vz/F) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters, Part 2: Number of Participants With Adverse Events (AEs) and Serious AEs, Part 2: Number of Participants With Severity of AEs, Part 2: Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Part 2: Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters, Part 2: Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters","Part 1: Number of Participants With Adverse Events (AEs) and Serious AEs, Part 1: Number of Participants Based on Severity of AEs, Part 1: Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Part 1: Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters, Part 1: Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters, Part 2: Analysis of Maximum Observed Plasma Concentration (Cmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate Pharmacokinetic (PK) Parameters, Part 2: Analysis of Time to Maximum Observed Plasma Concentration (Tmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters, Part 2: Analysis of Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (24 hours) at Steady State (AUC0-tau) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters, Part 2: Analysis of Plasma Trough Concentrations for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters, Part 2: Analysis of Apparent Terminal Elimination Half-life (t1/2) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters","Miami - United States, Miami - United States, Baltimore - United States",2024-03,2023-11-18,2024-02-15,INTERVENTIONAL,PHASE1
NCT05893043,GSBR-1290,"A Phase 1, Randomized, Double-blind, Placebo-controlled Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Volunteers","Gasherbrum Bio, Inc",Unknown,COMPLETED,18,2023-04-24,Healthy Volunteers,"GSBR-1290, Placebo","Number of Participants With Adverse Events (AEs) and Serious AEs, Number of Participants Based on Severity of AEs, Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters, Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters","Analysis of Maximum Observed Plasma Concentration (Cmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate Pharmacokinetic (PK) Parameters, Analysis of Time to Maximum Observed Plasma Concentration (Tmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters, Analysis of Plasma Trough Concentrations for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters, Analysis of Area Under the Plasma Concentration-time Curve (AUC) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters",Anaheim - United States,2023-06-28,2023-06-07,2023-07-14,INTERVENTIONAL,PHASE1
NCT05762471,GSBR-1290,"A Phase 1b/2a, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus on Metformin","Gasherbrum Bio, Inc",Unknown,COMPLETED,142,2023-01-09,"Overweight or Obesity, Type2 Diabetes Mellitus","GSBR-1290, Placebo","Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM","Analysis of Cmax at specified timepoints predose and postdose to calculate PK parameters, Analysis of Tmax at specified timepoints predose and postdose to calculate PK parameters, Analysis of AUC at specified timepoints predose and postdose to calculate PK parameters, Identification of GSBR-1290 metabolites following oral administration of multiple doses in plasma","Anaheim - United States, Chula Vista - United States, Miami - United States, Port Orange - United States",2024-04-11,2023-03-09,2024-04-25,INTERVENTIONAL,"PHASE1, PHASE2"
NCT02709876,RP-1,Unknown,Stem Cells Arabia,Unknown,UNKNOWN,50,2014-04,Retinitis Pigmentosa,Stem Cell Transplantation,ETDRS Visual acuity change,"Quality of Life: Questionnaire VFQ-25 (Visual Function Questionnaire-25), Color Vision: Ishihara Color Test, Contrast sensitivity: CSV-1000E",Amman - Jordan,2020-09,2016-03-16,2020-03-17,INTERVENTIONAL,"PHASE1, PHASE2"
NCT04776889,RP-1,"The Prognosis of Lipid Reprogramming With the HMG-CoA Reductase Inhibitor, Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients","National Cancer Institute, Egypt",Unknown,COMPLETED,70,2019-01-15,Prostate Cancer Metastatic,"Rosuvastatin 20mg, surgical castration","Lipid profile, Aggressiveness parameters, Aggressiveness parameters, Aggressiveness parameters, Aggressiveness parameters, Lipid metabolism parameters, Lipid metabolism parameters, Lipid metabolism parameters, Lipid metabolism parameters","short-term clinical outcome, short-term clinical outcome",Cairo - Egypt,2020-12-30,2021-03-02,2021-03-02,INTERVENTIONAL,PHASE4
NCT06264180,RP-1,"Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment",Replimune Inc.,Unknown,NOT_YET_RECRUITING,400,2024-06-01,Advanced Melanoma,"Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab, Pembrolizumab, Single-agent chemotherapy",Overall Survival (OS),"Progression Free Survival (PFS), Objective Response Rate (ORR)",No locations listed,2029-01-01,2024-02-16,2024-02-16,INTERVENTIONAL,PHASE3
NCT05858229,RP-1,A Phase 1B Study of Intralesional Injection of RP1 in Patients With Resectable Cutaneous SCC,Sherrif Ibrahim,Unknown,RECRUITING,12,2023-06-16,"Squamous Cell Carcinoma, RP1",RP1,Evaluate degree of pathologic response at 16 weeks.,"Evaluate the duration of response, Evaluate presence of disease, To estimate the complete response (CR) rate, To evaluate the disease control rate (DCR)",Victor - United States,2025-12,2023-05-15,2024-03-26,INTERVENTIONAL,"PHASE1, PHASE2"
NCT03767348,RP-1,"An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors",Replimune Inc.,IGNYTE,RECRUITING,340,2017-09-20,"Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC","RP1, nivolumab","Percentage of adverse events (AEs), Percentage of serious adverse events (SAEs), Percentage of dose limiting toxicities (DLTs), Percentage of overall response rate (ORR), Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RP1","Percentage of biologic activity, Percentage subjects with detectable RP1, Percentage of complete response (CR), Median duration of response, Median progression-free survival, Median overall survival","Birmingham - United States, Gilbert - United States, Phoenix - United States, Little Rock - United States, La Jolla - United States, Los Angeles - United States, Los Angeles - United States, Orange - United States, San Francisco - United States, Miami - United States, Iowa City - United States, Louisville - United States, Rochester - United States, Morristown - United States, New York - United States, New York - United States, Rochester - United States, Durham - United States, Cincinnati - United States, Portland - United States, Charleston - United States, Germantown - United States, Houston - United States, Murray - United States, Saint George - United States, Seattle - United States, Madison - United States, Besançon - France, Bordeaux - France, Dijon - France, Lyon - France, Marseille - France, Nice - France, Paris - France, Villejuif - France, Berlin - Germany, Essen - Germany, Kiel - Germany, Marburg - Germany, Barcelona - Spain, Barcelona - Spain, Barcelona - Spain, Madrid - Spain, Murcia - Spain, Pamplona - Spain, Sevilla - Spain, Valencia - Spain, Leeds - United Kingdom, Oxford - United Kingdom, Glasgow - United Kingdom, Bebington - United Kingdom, London - United Kingdom, Southampton - United Kingdom",2024-11,2018-12-06,2023-08-02,INTERVENTIONAL,PHASE2
NCT06395116,RP-1,"""Influence of Fabrication Technique on Microbial Adhesion and Biofilm Formation to Conventional, Milled, and 3D-Printed Resin Denture Base Materials",Menoufia University,Unknown,ACTIVE_NOT_RECRUITING,60,2023-01-20,"Inflammatory Response, Microbial Colonization, Denture Stomatitis",Denture base material,Biofilm formation,No secondary outcomes listed,Mansoura - Egypt,2024-07-04,2024-05-01,2024-05-01,OBSERVATIONAL,Not Available
NCT02786381,RP-1,Idylla Respiratory (IFV-RSV) Panel Clinical Testing and Sample Collection Protocol in Support of 510(k) Premarket Submission,"Janssen Pharmaceutica N.V., Belgium",RP1,COMPLETED,213,2015-11,"Respiratory Tract Infections, Influenza, Human, Respiratory Syncytial Virus Infections",No interventions listed,Product performance as measured by positive and negative agreement to a predicate,No secondary outcomes listed,Pensacola - United States,2016-10,2016-06-01,2016-11-22,OBSERVATIONAL,Not Available
NCT06216938,RP-1,Phase I Pilot Study of RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis,Yana Najjar,Unknown,RECRUITING,25,2024-02-02,Melanoma,Vusolimogene oderparepvec (RP1),Rate of Sentinel Lymph Node (SLN) Positivity,"Incidence of all treatment-emergent adverse events (TEAEs), Incidence of ≥ Grade 3 Treatment Emergent Adverse Events (TEAEs), Incidence of Serious Adverse Events (SAEs), Incidence of fatal Adverse Events (AEs), Incidence of all treatment-emergent adverse events (TEAEs) requiring withdrawal from RP1, Recurrence Free Survival (RFS), Overall Survival (OS)",Pittsburgh - United States,2026-01-31,2024-01-22,2024-03-04,INTERVENTIONAL,EARLY_PHASE1
NCT04349436,RP-1,"An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients With Advanced Cutaneous Malignancies",Replimune Inc.,ARTACUS,RECRUITING,65,2020-05-15,"Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Melanoma","RP1, intra-tumoral injection, oncolytic virus","Primary Safety Outcome Measure, Primary Efficacy Outcome Measure, Incidence of subjects with treatment-emergent adverse events greater than or equal to Grade 3, Incidence of subjects with Serious adverse events (SAEs), Incidence of subjects with fatal adverse events, Treatment-emergent adverse events requiring withdrawal from IP and incidence of organ allograft rejection","Duration of response (DOR) by investigator among subjects who experience Complete Response (CR) or Progressive Disease (PD), CR rate by investigator assessment, Disease control rate (DCR) by investigator review, Clinical benefit rate defined as the rate of Complete Response (CR), Partial Response (PR), or Stable Disease (SD), Progression Free Survival (PFS) by investigator review Duration of clinical benefit (DOCB) during active treatment and for up to one year after last treatment by investigator review, Overall survival (OS) at one year and two years, 3-year survival rate of subjects, Quality of life (QoL), as determined by patient-reported outcomes, Biologic activity as assessed by changes in individual tumor sizes, erythema, inflammation and necrosis, Disease-free Survival, To asses the efficacy of RP1 as determined by ORR in all transplant recipients treated, by investigator review","Phoenix - United States, La Jolla - United States, Los Angeles - United States, San Francisco - United States, Aurora - United States, Miami - United States, Tampa - United States, Chicago - United States, Ann Arbor - United States, New York - United States, New York - United States, Durham - United States, Cincinnati - United States, Columbus - United States, Pittsburgh - United States, Houston - United States, Richmond - United States",2027-09,2020-04-16,2024-03-01,INTERVENTIONAL,"PHASE1, PHASE2"
NCT04050436,RP-1,"A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma",Replimune Inc.,CERPASS,ACTIVE_NOT_RECRUITING,231,2019-10-08,"Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma","Cemiplimab, RP1","Objective Response Rate (ORR) according to blinded independent review, Complete Response Rate (CRR) according to blinded independent review","Progression Free Survival (PFS) by blinded independent review., ORR/CRR by investigator assessment and blinded independent review, ORR/CRR for patients with metastatic or locally advanced disease according to investigator review and blinded independent review, ORR/CRR for patients who have and have not previously received systemic CSCC-directed therapy and blinded independent review, Duration of Response (DOR) per investigator review and blinded independent review, Progression-free Survival (PFS) per investigator review, Overall Survival (OS), 3-year survival, Change in overall scores of patient-reported outcomes in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), Evaluation of the safety and tolerability of cemiplimab alone and combined with RP1 as assessed via adverse events (AEs)","La Jolla - United States, Los Angeles - United States, Stanford - United States, Aurora - United States, Miami - United States, Orlando - United States, Tampa - United States, Atlanta - United States, Hackensack - United States, New York - United States, Chapel Hill - United States, Columbus - United States, Greenville - United States, Houston - United States, Camperdown - Australia, Wollongong - Australia, Southport - Australia, Clayton - Australia, Melbourne - Australia, Melbourne - Australia, Nedlands - Australia, Panagyurishte - Bulgaria, Plovdiv - Bulgaria, Toronto - Canada, Besancon - France, Dijon - France, La Tronche - France, Lille - France, Lyon - France, Marseille - France, Nice - France, Paris - France, Pierre-Bénite - France, Villejuif - France, Berlin - Germany, Essen - Germany, Hamburg - Germany, Heidelberg - Germany, München - Germany, Tübingen - Germany, Athens - Greece, Athens - Greece, Athens - Greece, Athens - Greece, Bari - Italy, Gdańsk - Poland, Kraków - Poland, Warsaw - Poland, Wrocław - Poland, Barcelona - Spain, Barcelona - Spain, Madrid - Spain, Madrid - Spain, Murcia - Spain, Pamplona - Spain, Valencia - Spain",2025-09,2019-08-08,2024-04-02,INTERVENTIONAL,PHASE2
NCT04960579,RP-1,"Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)","Poseida Therapeutics, Inc.",MM,RECRUITING,231,2022-05-05,Multiple Myeloma,"P-BCMA-ALLO1 CAR-T cells, Rimiducid","Phase 1 Part 1: Assess the safety and maximum tolerated dose (MTD) of P-BCMA-ALLO1 based on dose limiting toxicities (DLT), Phase 1 Part 2: Assess the safety and tolerability of P-BCMA-ALLO1 when administered as a fixed dose of cells., Phase 1b: The effect of cell dose and study arm to guide selection of Recommended Phase 2 Dose (RP2D).","The safety of P-BCMA-ALLO1, The anti-myeloma effect of P-BCMA-ALLO1 (ORR) in Phase 1 Parts 1 and 2, The anti-myeloma effect of P-BCMA-ALLO1 (TTR), The anti-Myeloma effect of P-BCMA-ALLO1 (DOR), The anti-Myeloma effect of P-BCMA-ALLO1 (PFS), The anti-Myeloma effect of P-BCMA-ALLO1 (OS)","San Diego - United States, San Francisco - United States, Park Ridge - United States, Iowa City - United States, Kansas City - United States, Baltimore - United States, Detroit - United States, Buffalo - United States, Cincinnati - United States, Cleveland - United States, Oklahoma City - United States, Nashville - United States, Austin - United States, Houston - United States, San Antonio - United States",2027-12,2021-07-14,2024-06-21,INTERVENTIONAL,PHASE1
NCT03999021,RP-1,A Phase 1 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa,Johns Hopkins University,Unknown,ACTIVE_NOT_RECRUITING,30,2019-06-24,Retinitis Pigmentosa,NAC effervescent tablets,"Blood Pressure (mmHg), Tolerability of N-Acetylcysteine as assessed by drug-related symptoms, Tolerability of N-Acetylcysteine as assessed by time at which medication is taken, Tolerability of N-Acetylcysteine as assessed by number of times medication is taken per day","Change in best corrected visual acuity (BCVA), Change in central retinal sensitivity as assessed by microperimetry, Change in ellipsoid zone (EZ) width (µm), Change in aqueous reduced to oxidized glutathione ratio (GSH/GSSG), Change in serum carbonyl content (nmol/mg), Change in aqueous levels of N-Acetylcysteine (mg), Change in plasma levels of N-Acetylcysteine (µg/ml)",Baltimore - United States,2026-08,2019-06-26,2023-10-10,INTERVENTIONAL,PHASE1
NCT03063021,RP-1,A Phase 1 Open Label Dose Ranging Study to Assess the Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa (FIGHT-RP1 Study),Johns Hopkins University,FIGHT-RP1,COMPLETED,30,2017-02-15,Retinitis Pigmentosa,N-Acetyl Cysteine (NAC),Assessment of safety and tolerability of N-Acetylcysteine including incidence and severity of systemic and ocular adverse events (AEs) and changes from baseline vital signs and physical examination.,"Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 1 month after initiation of N-Acetylcysteine ., Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 2 months after initiation of N-Acetylcysteine ., Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 3 months after initiation of N-Acetylcysteine ., Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 4 months after initiation of N-Acetylcysteine ., Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 5 months after initiation of N-Acetylcysteine ., Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 6 months after initiation of N-Acetylcysteine ., Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 7 months after initiation of N-Acetylcysteine ., Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 8 months after initiation of N-Acetylcysteine ., Change from baseline aqueous and serum carbonyl content and GSH/GSSG ratio at 9 months after initiation of N-Acetylcysteine ., Change from baseline best corrected visual acuity (BCVA) 6 months after initiation of N-Acetylcysteine, Change from baseline central retinal sensitivity by microperimetry 3 months after initiation of N-Acetylcysteine, Change from baseline central retinal sensitivity by microperimetry 6 months after initiation of N-Acetylcysteine, Change from baseline central retinal sensitivity by microperimetry 9 months after initiation of N-Acetylcysteine, Change from baseline ellipsoid zone (EZ) width by spectral domain optical coherence tomography (SD-OCT) 6 months after initiation of N-Acetylcysteine, Change from baseline aqueous levels of N-Acetylcysteine, Change from baseline plasma levels of N-Acetylcysteine",Baltimore - United States,2019-02-11,2017-02-24,2022-09-19,INTERVENTIONAL,PHASE1
NCT06067061,RP-1,"""neoBREASTIM"": A Phase 2 Study of Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer (TNBC)",Institut Curie,neoBREASTIM,RECRUITING,51,2024-04-05,Triple Negative Breast Neoplasms,Atezolizumab + RP1,"Safety of the combination Atezolizumab plus RP1 oncolytic during the safety run-in phase, Toxicity of the combination Atezolizumab plus RP1 oncolytic immunotherapy during the safety run-in phase., Residual Cancer Burden (RCB) 0-1 during the phase II part","Response rate of RCB Score <= 1 at three cycles, Safety and toxicity of the combination Atezolizumab plus RP1 oncolytic immunotherapy, Invasive disease-free survival (iDFS), Percentage of TILs, Pre-treatment expression of Programmed Death-Ligand 1 (PD-L1), Correlation between RCB rates and response by Positron Emission Tomography-Scan (PET-CT) or breast MRI, RCB rates and response, Breast Conservation Surgery (BCS), Correlation between RCB rates and radiomics analyses",Paris - France,2026-04-05,2023-10-04,2024-05-30,INTERVENTIONAL,"PHASE1, PHASE2"
NCT04006457,Ritlecitinib,"A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA",Pfizer,ALLEGRO-LT,ACTIVE_NOT_RECRUITING,1051,2019-07-18,Alopecia Areata,"PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine","Number of subjects reporting treatment-emergent adverse events, Number of subjects reporting serious adverse events, Number of subjects reporting adverse events leading to discontinuation, Number of subjects with clinically significant abnormalities in vital signs, Number of subjects with clinically significant abnormalities in clinical laboratory values, Vaccine sub-study: Percentage of subjects with a tetanus booster response","Percentage of subjects with an absolute Severity of Alopecia Tool (SALT) Score <=10, Percentage of subjects with an absolute Severity of Alopecia Tool (SALT) Score <=20, Change from baseline in SALT score, Percentage of subjects with a 75% improvement in SALT score from baseline, Percentage of subjects with at least a 2 grade improvement or a score of 3 in Eyebrow Assessment (EBA) score, Percentage of subjects with at least a 2 grade improvement or a score of 3 in Eyelash Assessment (ELA) score, Patient's Global Impression of Change (PGI-C) response, defined as PGI-C score of ""moderately improved"" or ""greatly improved"", Change from baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) domains, Change from baseline in the depression subscale score of the Hospital Anxiety and Depression Scale (HADS), Change from baseline in the anxiety subscale score of the Hospital Anxiety and Depression Scale (HADS), Improvement on the Hospital Anxiety and Depression Scale (HADS) among participants with a baseline subscale score indicative of depression who achieved a ""normal"" subscale score indicative of an absence of depression, Improvement on the Hospital Anxiety and Depression Scale (HADS) among participants with a baseline subscale score indicative of anxiety who achieved a ""normal"" subscale score indicative of an absence of anxiety, Vaccine sub-study: Percentage of subjects with a meningococcal serogroup C response, Vaccine sub-study: Percentage of subjects with anti-tetanus antibody level ≥1.0 IU/mL, Vaccine sub-study: Percentage of subjects with anti-tetanus antibody level ≥0.1 IU/mL, Vaccine sub-study: Percentage of subjects with ≥4x increase in anti-tetanus antibody level from baseline, Vaccine sub-study: Fold increase in anti-tetanus levels above baseline values, Vaccine sub-study: Geometric mean concentrations (GMCs) of anti-tetanus antibody levels, Vaccine sub-study: Percentage of subjects with ≥1:4 hSBA (in subjects with undetectable pre-vaccination assay titers) for meningococcal serogroup C, Vaccine sub-study: Geometric mean titers (GMTs) of antibodies for meningococcal serogroup C, Number of subjects reporting treatment-emergent adverse events, Number of subjects reporting serious adverse events, Number of subjects reporting adverse events leading to discontinuation, Number of subjects with clinically significant abnormalities in vital signs, Number of subjects with clinically significant abnormalities in clinical laboratory values, Vaccine sub-study: Number of subjects reporting serious adverse events, Vaccine sub-study: Number of subjects reporting adverse events, Vaccine sub-study: Number of subjects reporting adverse events leading to discontinuation","Birmingham - United States, Birmingham - United States, Birmingham - United States, Beverly Hills - United States, Irvine - United States, Murrieta - United States, San Francisco - United States, San Francisco - United States, Santa Ana - United States, Aurora - United States, Aurora - United States, Aurora - United States, New Haven - United States, New Haven - United States, New Haven - United States, New Haven - United States, Washington - United States, Washington - United States, Washington - United States, Washington - United States, Washington - United States, Boynton Beach - United States, Orange Park - United States, Tampa - United States, Meridian - United States, Chicago - United States, Chicago - United States, Chicago - United States, Chicago - United States, Chicago - United States, Oakbrook Terrace - United States, Skokie - United States, Skokie - United States, Springfield - United States, Indianapolis - United States, Iowa City - United States, Chevy Chase - United States, Boston - United States, Minneapolis - United States, Minneapolis - United States, Minneapolis - United States, Omaha - United States, Verona - United States, New York - United States, New York - United States, New York - United States, Chapel Hill - United States, Chapel Hill - United States, Chapel Hill - United States, Chapel Hill - United States, Cleveland - United States, Tulsa - United States, Portland - United States, Portland - United States, Bellaire - United States, Vienna - United States, Caba - Argentina, Caba - Argentina, Kogarah - Australia, Kogarah - Australia, Benowa - Australia, Woolloongabba - Australia, Carlton - Australia, East Melbourne - Australia, Parkville - Australia, Parkville - Australia, Parkville - Australia, Winnipeg - Canada, Halifax - Canada, London - Canada, Markham - Canada, Markham - Canada, Oakville - Canada, Peterborough - Canada, Richmond Hill - Canada, Sudbury - Canada, Sudbury - Canada, Sudbury - Canada, Toronto - Canada, Toronto - Canada, Montreal - Canada, Quebec - Canada, Santiago - Chile, Santiago - Chile, Vina del Mar - Chile, Santiago - Chile, Beijing - China, Beijing - China, Guangzhou - China, Shenzhen - China, Wuhan - China, Nanjing - China, Shanghai - China, Hangzhou - China, Medellin - Colombia, Medellin - Colombia, Bogota D.C. - Colombia, Nachod - Czechia, Olomouc - Czechia, Praha 10 - Czechia, Praha 1 - Czechia, Bad Bentheim - Germany, Bad Bentheim - Germany, Berlin - Germany, Erlangen - Germany, Frankfurt am Main - Germany, Luebeck - Germany, Muenster - Germany, Nagoya - Japan, Sendai - Japan, Hamamatsu - Japan, Koto-ku - Japan, Mitaka-shi - Japan, Osaka - Japan, Tokyo - Japan, Busan - Korea, Republic of, Seoul - Korea, Republic of, Veracruz - Mexico, Veracruz - Mexico, Szczecin - Poland, Grodzisk Mazowiecki - Poland, Krakow - Poland, Lodz - Poland, Ostrowiec Swietokrzyski - Poland, Szczecin - Poland, Warszawa - Poland, Warszawa - Poland, Warszawa - Poland, Warszawa - Poland, Wroclaw - Poland, Wroclaw - Poland, Wroclaw - Poland, Chelyabinsk - Russian Federation, Kirov - Russian Federation, Moscow - Russian Federation, Moscow - Russian Federation, Rostov-on-Don - Russian Federation, Saint Petersburg, - Russian Federation, Saint Petersburg - Russian Federation, Saint Petersburg - Russian Federation, Yaroslavl - Russian Federation, Badalona - Spain, Barcelona - Spain, Cordoba - Spain, Madrid - Spain, Madrid - Spain, Madrid - Spain, Valencia - Spain, Taichung - Taiwan, Kaohsiung City - Taiwan, Kaohsiung - Taiwan, New Taipei City - Taiwan, Taipei - Taiwan, Taoyuan City - Taiwan, Southampton - United Kingdom, Southampton - United Kingdom, Brighton - United Kingdom, Glasgow - United Kingdom, London - United Kingdom, London - United Kingdom, London - United Kingdom",2024-07-08,2019-07-05,2023-12-22,INTERVENTIONAL,PHASE3
NCT06163326,Ritlecitinib,"A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TITRATION, MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY, EFFICACY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO",Pfizer,Tranquillo LTE,RECRUITING,400,2024-01-19,Vitiligo,"Ritlecitinib, Ritlecitinib 100 mg, Placebo","Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuation, Incidence of clinically significant laboratory abnormalities","Response based on T-VASI75 at weeks 4, 8, 12, 24, 36 and 52, Response based on F-VASI75 at weeks 4, 8, 12, 24, 36 and 52, Response based on T-VASI50 at weeks 4, 8, 12, 24, 36 and 52, Response based on F-VASI50 at weeks 4, 8, 12, 24, 36 and 52, Response based on T-VASI90 at weeks 4, 8, 12, 24, 36 and 52, Response based on F-VASI90 at weeks 4, 8, 12, 24, 36 and 52, Response based on T-VASI100 at weeks 4, 8, 12, 24, 36 and 52, Response based on F-VASI100 at weeks 4, 8, 12, 24, 36 and 52, Patient Global Impression of Severity-Face (PGIS-F) at weeks 24, 36, and 52, Patient Global Impression of Severity-Overall Vitiligo (PGIS-V) at weeks 24, 36, and 52, Patient Global Impression of Change-Face (PGIC-F) at week 24, 36, and 52, Patient Global Impression of Change- Overall vitiligo (PGIC-V) at weeks 24, 36, and 52, Proportion of participants achieving disease stabilization, Percentage change from baseline (%CFB) in F-VASI at weeks 4, 8, 12, 24, 36, and 52, Percentage change from baseline (%CFB) in T-VASI at weeks 4, 8, 12, 24, 36, and 52","Encinitas - United States, Huntington Beach - United States, Los Angeles - United States, Boynton Beach - United States, Hollywood - United States, Tampa - United States, Indianapolis - United States, Baton Rouge - United States, Largo - United States, Wilmington - United States, Wilmington - United States, Columbus - United States, Columbus - United States, Houston - United States, Red Deer - Canada, Markham - Canada, Mississauga - Canada, Toronto - Canada, Quebec - Canada, Quebec - Canada, Shanghai - China, Sendai-shi - Japan, Sakai City - Japan, Bunkyo-ku - Japan, Shinjuku-ku - Japan, Kofu - Japan, Tokyo - Japan, Suwon - Korea, Republic of, Seoul - Korea, Republic of, Osielsko - Poland, Warszawa - Poland, Szczecin - Poland",2027-01-30,2023-12-08,2024-06-26,INTERVENTIONAL,PHASE3
NCT05879458,Ritlecitinib,"A Single-center, Single-arm, Open-label Phase IIA Clinical Trial to Investigate Efficacy and Safety of Ritlecitinib (PF-06651600) in Patients With Cutaneous T Cell Lymphomas",Icahn School of Medicine at Mount Sinai,Unknown,RECRUITING,20,2023-05-17,"CTCL, Mycosis Fungoides, Sezary Syndrome",Ritlecitinib,Change in Modified Severity Weighted Assessment Tool (mSWAT),"Change in Modified Severity Weighted Assessment Tool (mSWAT), Treatment Emergent Adverse Events, Number of Serious Adverse Events, Number of Adverse Events, Number of clinically significant abnormalities in vital signs, Number of clinically significant abnormalities in clinical laboratory values, Change in Percentage of patients achieving 50% or greater improvement in mSWAT score, Change in Global Response Score, Absolute change of health-related quality of life (Skindex-29), Absolute change of health-related quality of life (FACT-G), Absolute change of IPQ-R (Illness perception questionnaire), Percentage change of pruritus according to visual analogue scale (VAS)",New York - United States,2026-04,2023-05-30,2024-05-07,INTERVENTIONAL,PHASE2
NCT05128058,Ritlecitinib,"AN OPEN LABEL, PHASE 1, TWO-ARM STUDY TO ASSESS TARGET OCCUPANCY AND FUNCTIONAL INHIBITION OF JAK3 AND TEC KINASES BY SINGLE DOSES OF RITLECITINIB IN HEALTHY ADULT PARTICIPANTS",Pfizer,Unknown,COMPLETED,16,2021-10-22,Healthy,"Ritlecitinib 50 mg, Ritlecitinib 200 mg","Percent Target Occupancy for JAK3, Percent Target Occupancy for BTK, Percent Target Occupancy for ITK, Percent Target Occupancy for TXK, Percent Target Occupancy for TEC, Percent Target Occupancy for BMX","Maximum Observed Plasma Concentration (Cmax) of Ritlecitinib, Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ritlecitinib, Last Quantifiable Plasma Concentration (Clast) of Ritlecitinib, Average Plasma Concentration From Time 0 to 24 Hours (Cav) of Ritlecitinib, Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Ritlecitinib, Area Under the Curve From Time 0 to 24 Hours (AUC24) of Ritlecitinib, Number of Participants With All-Causality and Treatment-Related Treatment-Emergent Adverse Events (TEAEs), Number of Participants With Treatment-Emergent Adverse Events by Severity, Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality, Number of Participants With Pre-defined Criteria for Vital Signs",New Haven - United States,2022-01-14,2021-11-19,2023-11-13,INTERVENTIONAL,PHASE1
NCT05743244,Ritlecitinib,"A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subtype-Selective JAK Inhibitors for Preservation of Pancreatic β Cell Function in Newly Diagnosed Type 1 Diabetes Mellitus",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Unknown,RECRUITING,78,2023-10-19,"Diabetes Mellitus, Type 1","Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo",The area under the stimulated C-peptide curve (Y_AUC),No secondary outcomes listed,"Orange - United States, Palo Alto - United States, San Francisco - United States, Aurora - United States, New Haven - United States, Gainesville - United States, Tampa - United States, Atlanta - United States, Indianapolis - United States, Minneapolis - United States, Kansas City - United States, New York - United States, Pittsburgh - United States, Nashville - United States, Dallas - United States, Seattle - United States",2026-06-30,2023-02-24,2024-05-24,INTERVENTIONAL,PHASE2
NCT05852340,Ritlecitinib,"A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF PEDIATRIC RITLECITINIB (PF-06651600) SPRINKLED IN APPLESAUCE, YOGHURT AND STRAWBERRY JAM RELATIVE TO INTACT BLEND-IN CAPSULE OF RITLECITINIB AND THE EFFECT OF FOOD ON THE BIOAVAILABILITY OF THE INTACT BLEND-IN CAPSULE DOSAGE FORMULATION OF RITLECITINIB IN HEALTHY ADULT PARTICIPANTS",Pfizer,Unknown,COMPLETED,12,2023-05-09,"Healthy Volunteers, Adult, Pharmacokinetics",Ritlecitinib,"Maximum plasma concentration (Cmax), Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf)",Number of participants reporting adverse events,Brussels - Belgium,2023-07-12,2023-05-10,2023-08-02,INTERVENTIONAL,PHASE1
NCT04655040,Ritlecitinib,"A PHASE 1, 2-PERIOD, FIXED-SEQUENCE, MULTIPLE-DOSE, OPEN-LABEL STUDY TO ESTIMATE THE EFFECTS OF RITLECITINIB (PF-06651600) ON THE PHARMACOKINETICS OF A SINGLE DOSE OF CAFFEINE IN HEALTHY PARTICIPANTS",Pfizer,Unknown,COMPLETED,12,2020-12-18,Healthy Participants,"Caffeine, Ritlecitinib",Area under the plasma concentration-time profile from time 0 extrapolated to infinity (AUCinf) of caffeine,"Incidence of treatment-emergent adverse events, Incidence of clinically significant abnormalities in vital signs, Incidence of clinically significant abnormalities in clinical laboratory values",New Haven - United States,2021-03-05,2020-12-04,2021-03-18,INTERVENTIONAL,PHASE1
NCT06172348,Ritlecitinib,"A PHASE 1, OPEN-LABEL STUDY IN HEALTHY PARTICIPANTS TO INVESTIGATE THE PHARMACOKINETICS OF RITLECITINIB FOLLOWING SINGLE ORAL ADMINISTRATION OF MODIFIED RELEASE FORMULATIONS UNDER FED AND FASTED CONDITIONS",Pfizer,Unknown,COMPLETED,12,2024-02-01,Healthy Volunteers,Ritlecitinib,"Maximum plasma concentration (Cmax), Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf) if data permit, otherwise area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast)","Frequency of adverse events, Frequency of abnormal clinical laboratory tests, Frequency of abnormal vital signs, Frequency of abnormal 12-lead ECG",Brussels - Belgium,2024-03-28,2023-12-15,2024-04-04,INTERVENTIONAL,PHASE1
NCT05583526,Ritlecitinib,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO",Pfizer,Tranquillo,RECRUITING,600,2022-12-01,"Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo","Ritlecitinib, Placebo","US only Co-Primary Endpoints: Response based on Total body Vitiligo Area Scoring Index 75 (T-VASI75) at Week 52 and T-VASI50 at Week 52, Global (Other than US): Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52, Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events (AEs), leading to discontinuation, and clinically significant laboratory abnormalities","US-Only: Response based on F-VASI75 at 24, 26 and 52 weeks, US-Only: Response based on T-VASI50 at 24 and 36 weeks, Global (Other than US):Patient Global Impression of Severity-Face (PGIS-F), Global (Other than US): Patient Global Impression of Severity-Overall Vitiligo (PGIS-V), Global (Other Than US): Response based on T-VASI50 at Week 52, Patient Global Impression of Change-Face (PGIC-F), Patient Global Impression of Change- Overall vitiligo(PGIC-V), Global (Other than US): Response based on F-VASI75 at 24 and 36 weeks, Global (Other than US): Response based on PGIS-V, Global (Other than US): Response based on F-VASI75, Change from baseline in Dermatology Life Quality Index (DLQI) or Children Dermatology Life Quality Index (CDLQI), Proportion of participants achieving disease stabilization, Response based on T-VASI50, Response based on F-VASI75, US only: Response based on T-VASI75, Global (Other than US): Response based on T-VASI75, All Countries: Time to rescue medication, Percentage change from baseline in F-VASI, Percentage change from baseline in T-VASI, Response based on T-VASI90, Response based on T-VASI100, Response based on F-VASI50, Response based on F-VASI90, Response based on F-VASI100, Change from baseline in the Hospital Anxiety and Depression Scale (HADS), The proportion of patients achieving absence of depression on HADS depression subscale, The proportion of patients achieving absence of anxiety on HADS anxiety subscale, US-Only: Patient Global Impression of Severity-Face (PGIS-F), US-Only: Patient Global Impression of Severity-Overall Vitiligo (PGIS-V)","Birmingham - United States, Birmingham - United States, Encinitas - United States, Fremont - United States, Huntington Beach - United States, Los Angeles - United States, Washington - United States, Washington - United States, Washington - United States, Boynton Beach - United States, Hollywood - United States, Lutz - United States, Miami - United States, Miami - United States, North Miami Beach - United States, North Miami Beach - United States, North Miami Beach - United States, Saint Petersburg - United States, Tampa - United States, Tampa - United States, Marietta - United States, Sandy Springs - United States, Indianapolis - United States, Baton Rouge - United States, Baton Rouge - United States, Baton Rouge - United States, New Orleans - United States, Prairieville - United States, Glenn Dale - United States, Largo - United States, Rockville - United States, Boston - United States, Brighton - United States, Worcester - United States, Ann Arbor - United States, Canton - United States, Omaha - United States, Albuquerque - United States, Brooklyn - United States, New York - United States, Chapel Hill - United States, Chapel Hill - United States, Wilmington - United States, Wilmington - United States, Wilmington - United States, Cleveland - United States, Columbus - United States, Columbus - United States, Charleston - United States, Bellaire - United States, Dallas - United States, Houston - United States, Houston - United States, Houston - United States, San Antonio - United States, San Antonio - United States, San Antonio - United States, Darlinghurst - Australia, Campbelltown - Australia, Carlton - Australia, East Melbourne - Australia, East Melbourne - Australia, Melbourne - Australia, Dupnitsa - Bulgaria, Sofia - Bulgaria, Stara Zagora - Bulgaria, Calgary - Canada, Red Deer - Canada, Cobourg - Canada, Markham - Canada, Mississauga - Canada, Oshawa - Canada, Toronto - Canada, Quebec - Canada, Quebec - Canada, Fuzhou - China, Guangzhou - China, Guangzhou - China, Wuhan - China, Shenyang - China, Shanghai - China, Tianjin - China, Kunming - China, Hangzhou - China, Hangzhou - China, Wenzhou - China, Wenzhou - China, Stuttgart - Germany, Erlangen - Germany, Bad Bentheim - Germany, Münster - Germany, Roma - Italy, Brescia - Italy, Rozzano - Italy, Rozzano - Italy, Rozzano - Italy, Roma - Italy, Roma - Italy, Bologna - Italy, Brescia - Italy, Nagoya - Japan, Sendai-shi - Japan, Sakai City - Japan, Shinjuku-ku - Japan, Toshima-Ku - Japan, Kofu - Japan, Tokyo - Japan, Tokyo - Japan, Goyang-si - Korea, Republic of, Suwon-si - Korea, Republic of, Suwon - Korea, Republic of, Seoul - Korea, Republic of, Mexico City - Mexico, Monterrey - Mexico, Veracruz - Mexico, Veracruz - Mexico, Veracruz - Mexico, Osielsko - Poland, Warszawa - Poland, Szczecin - Poland, Szczecin - Poland, Lodz - Poland, Ostrowiec Witokrzyski - Poland, Mthatha - South Africa, Port Elizabeth - South Africa, Kempton Park - South Africa, Pretoria - South Africa, Cape Town - South Africa, Cordoba - Spain, Las Palmas de Gran Canaria - Spain, Barcelona - Spain, Córdoba - Spain, Madrid - Spain, Madrid - Spain, Istanbul - Turkey, Istanbul - Turkey, Kayseri - Turkey, Manisa - Turkey, London - United Kingdom",2025-07-28,2022-10-17,2024-06-03,INTERVENTIONAL,PHASE3
NCT06373458,Ritlecitinib,"A Single-Center, Two-Arm, Open-Label Phase IIA Clinical Trial to Investigate Efficacy and Safety of Ritlecitinib in Patients With Keloid",Icahn School of Medicine at Mount Sinai,Unknown,RECRUITING,30,2024-06-30,Keloid,Ritlecitinib,"Recurrence Rate, Change in Detroid Keloid Scale Score","Change in Peak keloid tension, Change in Detroid Keloid Scale Score (DKS), Change in Pain Numerical Rating Scale (Pain-NRS), Change in Itch-NRS, Change in PGIC (Patient Global Impression of Change), Change in DLQI (Dermatology Life Quality Index)",New York - United States,2026-03,2024-04-18,2024-06-04,INTERVENTIONAL,PHASE2
NCT05549934,Ritlecitinib,A Pilot Study to Assess Safety and Biomarker Responses of Ritlecitinib (JAK3/TEC Inhibitor) in Cicatricial Alopecia,Emma Guttman,Unknown,RECRUITING,50,2022-12-15,Cicatricial Alopecia,PF-06651600,"Number of Treatment-Emergent Adverse Events, Severity of Treatment-Emergent Adverse Events, Change in Ct values of mRNA levels of CCL5 gene, Change in Ct values of mRNA levels of CCL5 gene","Change in Ct values of mRNA levels of CXCR3, Ct value of mRNA levels of CXCR3, The Frontal Fibrosis Alopecia Severity Index (FFASI), The Frontal Fibrosis Alopecia Severity Index (FFASI), The Frontal Fibrosis Alopecia Severity Index (FFASI), The Lichen Planopilaris Activity Index (LPPAI), The Lichen Planopilaris Activity Index (LPPAI)",New York - United States,2024-12,2022-09-22,2023-08-14,INTERVENTIONAL,PHASE2
NCT05097716,Ritlecitinib,"PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY TO ESTIMATE THE EFFECT OF MULTIPLE-DOSE RITLECITINIB (PF-06651600) ON THE PHARMACOKINETICS OF SINGLE-DOSE TOLBUTAMIDE IN HEALTHY PARTICIPANTS",Pfizer,Unknown,COMPLETED,12,2021-11-02,Healthy Volunteers,"Ritlecitinib, Tolbutamide","Maximum Plasma Concentration (Cmax) of Tolbutamide Administered With and Without Ritlecitinib, Area Under the Plasma Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Tolbutamide Administered With and Without Ritlecitinib",Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - All Causalities and Treatment Related,New Haven - United States,2022-01-10,2021-10-28,2023-10-06,INTERVENTIONAL,PHASE1
NCT05040295,Ritlecitinib,"A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSS-OVER, SINGLE DOSE STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF PEDIATRIC RITLECITINIB (PF-06651600) CAPSULES AND SPRAY CONGEALED BEADS RELATIVE TO ADULT CAPSULES IN HEALTHY ADULT PARTICIPANTS",Pfizer,Unknown,COMPLETED,12,2021-09-10,Healthy Participants,"ritlecitinib, ritlecitinib, ritlecitinib","Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for Ritlecitinib, Maximum Plasma Concentration (Cmax) for Ritlecitinib","Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related), Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality",New Haven - United States,2021-11-19,2021-09-10,2023-08-21,INTERVENTIONAL,PHASE1
NCT04413617,Ritlecitinib,"A 24-WEEK RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, ACTIVE COMPARATOR, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600 (RITLECITINIB) AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH MODERATELY-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE",Pfizer,Unknown,COMPLETED,460,2020-07-29,Rheumatoid Arthritis,"PF-06650833, PF-06651600, Tofacitinib",Change From Baseline (BL) in Disease Activity Score (DAS)28-C Reactive Protein (CRP) at Week 12,"DAS28-CRP Remission (<2.6) Rates at Week 24, Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), and Withdrawals Due to TEAEs, Number of Participants With Clinical Laboratory Abnormalities (Hematology and Chemistry, Without Regard to Baseline Abnormality), Number of Participants With Change From Baseline in Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria, Number of Participants With Adverse Events of Special Interest, Change From Baseline in DAS28-CRP at Week 24, American College of Rheumatology (ACR)20, ACR 50, ACR 70, and ACR 90 Responder Rates at Week 12 and Week 24, Change From Baseline in the Tender/Painful and Swollen Joint Count at Week 12 and Week 24, Change From Baseline in the Physician's Global Assessment (PhGA) of Arthritis at Week 12 and Week 24","Pleven - Bulgaria, Plovdiv - Bulgaria, Plovdiv - Bulgaria, Plovdiv - Bulgaria, Plovdiv - Bulgaria, Ruse - Bulgaria, Ruse - Bulgaria, Sofia - Bulgaria, Sofia - Bulgaria, Sofia - Bulgaria, Sofia - Bulgaria, Sofia - Bulgaria, Winnipeg - Canada, Rimouski - Canada, Santiago - Chile, Santiago - Chile, Santiago - Chile, Santiago - Chile, Santiago - Chile, Santiago - Chile, Pardubice - Czechia, Brno - Czechia, Brno - Czechia, Brno - Czechia, Havirov - Czechia, Ostrava - Kuncice - Czechia, Ostrava - Czechia, Ostrava - Czechia, Ostrava - Czechia, Pardubice - Czechia, Pardubice - Czechia, Praha 2 - Czechia, Praha 4 - Czechia, Uherske Hradiste - Czechia, Uherske Hradiste - Czechia, Uherske Hradiste - Czechia, Tbilisi - Georgia, Tbilisi - Georgia, Tbilisi - Georgia, Tbilisi - Georgia, Tbilisi - Georgia, Bekescsaba - Hungary, Bekescsaba - Hungary, Budapest - Hungary, Budapest - Hungary, Budapest - Hungary, Budapest - Hungary, Budapest - Hungary, Budapest - Hungary, Budapest - Hungary, Budapest - Hungary, Budapest - Hungary, Budapest - Hungary, Budapest - Hungary, Debrecen - Hungary, Debrecen - Hungary, Gyula - Hungary, Kistarcsa - Hungary, Kistarcsa - Hungary, Miskolc - Hungary, Szeged - Hungary, Szeged - Hungary, Szeged - Hungary, Veszprem - Hungary, Veszprém - Hungary, Bialystok - Poland, Bialystok - Poland, Bialystok - Poland, Bialystok - Poland, Bialystok - Poland, Bialystok - Poland, Bydgoszcz - Poland, Bydgoszcz - Poland, Bydgoszcz - Poland, Gdynia - Poland, Gdynia - Poland, Gdynia - Poland, Grodzisk Mazowiecki - Poland, Grodzisk Mazowiecki - Poland, Krakow - Poland, Krakow - Poland, Krakow - Poland, Krakow - Poland, Krakow - Poland, Krakow - Poland, Krakow - Poland, Krakow - Poland, Nowa Sol - Poland, Nowa Sol - Poland, Nowy Tomysl - Poland, Poznan - Poland, Poznan - Poland, Poznan - Poland, Poznan - Poland, Poznan - Poland, Warszawa - Poland, Warszawa - Poland, Warszawa - Poland, Warszawa - Poland, Warszawa - Poland, Warszawa - Poland, Warszawa - Poland, Warszawa - Poland, Warszawa - Poland, Bratislava - Slovakia, Bratislava - Slovakia, Bratislava - Slovakia, Kosice - Slovakia, Kosice - Slovakia, Kosice - Slovakia, Kosice - Slovakia, Martin - Slovakia, Martin - Slovakia, Martin - Slovakia, Nitra - Slovakia, Partizanske - Slovakia, Partizanske - Slovakia, Partizanske - Slovakia, Piestany - Slovakia, Piestany - Slovakia, Piestany - Slovakia, Rimavska Sobota - Slovakia, Rimavska Sobota - Slovakia, Rimavska Sobota - Slovakia, Rimavska Sobota - Slovakia, Ruzomberok - Slovakia, Topolcany - Slovakia, Santiago de Compostela - Spain, Santiago de Compostela - Spain, Elche - Spain, Barcelona - Spain, Santiago de Compostela - Spain, Sevilla - Spain, Chernihiv - Ukraine, Kharkiv - Ukraine, Kyiv - Ukraine, Kyiv - Ukraine, Kyiv - Ukraine, Kyiv - Ukraine, Kyiv - Ukraine, Kyiv - Ukraine, Odesa - Ukraine, Poltava - Ukraine, Zaporizhzhya - Ukraine",2022-02-07,2020-06-04,2023-04-07,INTERVENTIONAL,PHASE2
NCT04517864,Ritlecitinib,"A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE SAFETY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH ALOPECIA AREATA",Pfizer,Allegro2a,TERMINATED,71,2020-09-15,Alopecia Areata,"PF-06651600, Placebo","Change From Baseline in I-V Interwave Latency on Brainstem Auditory Evoked Potentials (BAEP) at a Stimulus Intensity of 80 Decibels (dB) From the Right Side at Month 9, Change From Baseline in I-V Interwave Latency on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 9","Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 6, Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 9E and 15E, Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 6, Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 9E and 15E, Change From Baseline in Percentage of Intraepidermal Nerve Fiber (IENF) With Axonal Swelling in Skin Punch Biopsies at Month 9, Change From Baseline in Percentage of IENFs With Axonal Swelling in Skin Punch Biopsies at Month 15E, Change From Baseline in Intraepidermal Nerve Fiber Density (IENFD) in Skin Punch Biopsies at Month 9, Change From Baseline in IENFD in Skin Punch Biopsies at Month 15E, Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Right Side at Month 6 and Month 9, Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Right Side at Month 9E and 15E, Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 6 and Month 9, Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 9E and 15E, Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Right Side up to Month 9, Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Right Side at Baseline, Month 3E, 6E, 9E and 15E, Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Left Side up to Month 9, Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Left Side at Baseline, Month 3E, 6E, 9E and 15E, Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs), Number of Participants Who Discontinued From Study Due to Adverse Event (AEs), Number of Participants Who Discontinued Study Drug Due to AE and Continued Study, Number of Participants With Temporary Drug Discontinuation Due to AEs, Number of Participants With Clinically Significant Abnormalities in Vital Signs, Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values, Change From Baseline in Overall Severity of Alopecia Tool (SALT) Scores up to Month 9, Change From Baseline in Overall SALT Scores at Month 3E, 6E, 9E, 12E and 15E, Change From Baseline in Alopecia Areata - Severity of Alopecia Tool (AA-SALT) Score up to Month 9, Change From Baseline in AA-SALT Score at Month 3E, 6E, 9E, 12E and 15E, Number of Participants With Patient's Global Impression of Change (PGI-C) Response up to Month 9, Number of Participants With PGI-C Response at 3E, 6E, 9E, 12E and 15E","Huntington Beach - United States, Irvine - United States, Boca Raton - United States, Hollywood - United States, Hollywood - United States, Jacksonville - United States, Jacksonville - United States, Miami - United States, Miramar - United States, Orlando - United States, Oviedo - United States, Tampa - United States, Skokie - United States, Skokie - United States, Saint Louis - United States, Albuquerque - United States, Albuquerque - United States, Stony Brook - United States, Raleigh - United States, Austin - United States, Houston - United States, Franklin - United States, Lynchburg - United States, Norfolk - United States, Kogarah - Australia, Box Hill - Australia, East Melbourne - Australia, Markham - Canada, Peterborough - Canada, Verdun - Canada, Quebec - Canada, Bialystok - Poland, Katowice - Poland, Krakow - Poland, Ostrowiec Swietokrzyski - Poland, Warszawa - Poland, Warszawa - Poland, Warszawa - Poland, Wroclaw - Poland, Wrocław - Poland",2022-01-04,2020-08-18,2024-06-18,INTERVENTIONAL,PHASE2
NCT05522556,Ritlecitinib,Unknown,Pfizer,Unknown,AVAILABLE,Unknown,Unknown Date,Alopecia Areata,Ritlecitinib,No primary outcomes listed,No secondary outcomes listed,No locations listed,Unknown Date,2022-08-31,2023-11-13,EXPANDED_ACCESS,Not Available
NCT03732807,Ritlecitinib,"A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS",Pfizer,ALLEGRO-2b/3,COMPLETED,718,2018-12-03,Alopecia Areata,"PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2, PF-06651600 Maintenance Dose #3, Placebo",Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24,"Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4, Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1, Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24, Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model, Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model, Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48, Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48, Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48, Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24, Change From Baseline in SALT Score at Week 28, 34, 40, and 48, Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48, Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48, Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48, Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations, Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations, Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48","Birmingham - United States, Birmingham - United States, Birmingham - United States, Beverly Hills - United States, Irvine - United States, Murrieta - United States, San Francisco - United States, San Francisco - United States, Santa Ana - United States, Aurora - United States, Aurora - United States, Aurora - United States, New Haven - United States, New Haven - United States, Washington - United States, Washington - United States, Washington - United States, Washington - United States, Boynton Beach - United States, Orange Park - United States, Tampa - United States, Meridian - United States, Chicago - United States, Chicago - United States, Chicago - United States, Chicago - United States, Chicago - United States, Skokie - United States, Springfield - United States, Indianapolis - United States, Iowa City - United States, Iowa City - United States, Chevy Chase - United States, Boston - United States, Minneapolis - United States, Minneapolis - United States, Omaha - United States, Verona - United States, New York - United States, New York - United States, Chapel Hill - United States, Chapel Hill - United States, Chapel Hill - United States, Cleveland - United States, Tulsa - United States, Houston - United States, Caba - Argentina, Caba - Argentina, Kogarah - Australia, Kogarah - Australia, Benowa - Australia, Woolloongabba - Australia, Carlton - Australia, East Melbourne - Australia, Parkville - Australia, Parkville - Australia, Winnipeg - Canada, Halifax - Canada, London - Canada, Markham - Canada, Oakville - Canada, Peterborough - Canada, Richmond Hill - Canada, Sudbury - Canada, Sudbury - Canada, Toronto - Canada, Montreal - Canada, Quebec - Canada, Santiago - Chile, Santiago - Chile, Santiago - Chile, Vina del Mar - Chile, Beijing - China, Beijing - China, Beijing - China, Guangzhou - China, Shenzhen - China, Wuhan - China, Nanjing - China, Shanghai - China, Hangzhou - China, Hangzhou - China, Shanghai - China, Medellin - Colombia, Medellin - Colombia, Bogota - Colombia, Nachod - Czechia, Olomouc - Czechia, Praha 10 - Czechia, Praha 1 - Czechia, Praha 8- Liben - Czechia, Bad Bentheim - Germany, Berlin - Germany, Erlangen - Germany, Frankfurt am Main - Germany, Luebeck - Germany, Muenster - Germany, Budapest - Hungary, Debrecen - Hungary, Gyongyos - Hungary, Szeged - Hungary, Nagoya - Japan, Sendai - Japan, Hamamatsu - Japan, Koto-ku - Japan, Shinjuku-ku - Japan, Osaka - Japan, Busan - Korea, Republic of, Seoul - Korea, Republic of, Veracruz - Mexico, Veracruz - Mexico, Krakow - Poland, Lodz - Poland, Lodz - Poland, Lodz - Poland, Szczecin - Poland, Warszawa - Poland, Warszawa - Poland, Wroclaw - Poland, Chelyabinsk - Russian Federation, Kirov - Russian Federation, Moscow - Russian Federation, Moscow - Russian Federation, Rostov-on-Don - Russian Federation, Saint Petersburg, - Russian Federation, Saint Petersburg - Russian Federation, Saint Petersburg - Russian Federation, Yaroslavl - Russian Federation, Badalona - Spain, Barcelona - Spain, Cordoba - Spain, Cordoba - Spain, Cordoba - Spain, Madrid - Spain, Madrid - Spain, Valencia - Spain, Valencia - Spain, Valencia - Spain, Kaohsiung City - Taiwan, Kaohsiung - Taiwan, New Taipei City - Taiwan, Taichung - Taiwan, Taichung - Taiwan, Taipei - Taiwan, Taoyuan City - Taiwan, Brighton - United Kingdom, Southampton - United Kingdom, Brighton - United Kingdom, Dundee - United Kingdom, Glasgow - United Kingdom, Glasgow - United Kingdom, Hampshire - United Kingdom, London, - United Kingdom, London, - United Kingdom, London - United Kingdom",2020-12-31,2018-11-07,2022-02-24,INTERVENTIONAL,"PHASE2, PHASE3"
NCT06072183,Ritlecitinib,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBO-CONTROLLED MULTI-CENTER STUDY WITH A DOUBLE-BLIND 52-WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UP/DOSE DOWN TITRATION INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO",Pfizer,Tranquillo 2,RECRUITING,1450,2023-11-08,"Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo","Ritlecitinib, Ritlecitinib, Placebo","US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and Total body Vitiligo Area Scoring Index 50 (T-VASI50) at Week 52, Global (Other than US): Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52, Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) leading to discontinuation., Incidence of Clinically significant laboratory abnormalities.","Response based on F-VASI75 at 24 and 36 weeks, US-Only: Response based on T-VASI50 at 24 and 36 weeks, Global (Other than US):Patient Global Impression of Severity-Face (PGIS-F), Global (Other than US): Patient Global Impression of Severity-Overall Vitiligo (PGIS-V), Global (Other Than US): Response based on T-VASI50 at Week 24, 36 and 52, Patient Global Impression of Change-Face (PGIC-F), Patient Global Impression of Change- Overall vitiligo(PGIC-V), Change from baseline in Dermatology Life Quality Index (DLQI), Proportion of participants achieving disease stabilization, Response based on T-VASI50, Response based on F-VASI75, Response based on T-VASI75, Global (Other than US): Response based on T-VASI75, Proportion of participants with sustained improvement in T-VASI, Proportion of participants with sustained improvement in F-VASI, Time to rescue medication use, US-Only: Percentage change from baseline (% CFB) in F-VASI at Weeks 24, 36 and 52, US-Only: % CFB in T-VASI at weeks 24, 36 and 52, Response based on T-VASI90, Response based on T-VASI100, Response based on F-VASI50, Change from baseline in the Hospital Anxiety and Depression Scale (HADS), The proportion of patients achieving absence of depression on HADS depression subscale, The proportion of patients achieving absence of anxiety on HADS anxiety subscale, US-Only: Patient Global Impression of Severity-Face (PGIS-F), US-Only: Patient Global Impression of Severity-Overall Vitiligo (PGIS-V), % CFB in F-VASI at Week 4, 8, 12, 48, 56, 60, 64, 76, 88 and 104., % CFB in T-VASI at Week 4, 8, 12, 48, 56, 60, 64, 76, 88 and 104.","Birmingham - United States, Birmingham - United States, Scottsdale - United States, Bryant - United States, Fountain Valley - United States, Los Angeles - United States, Oxnard - United States, Rancho Santa Margarita - United States, Rancho Santa Margarita - United States, Rolling Hills Estates - United States, San Diego - United States, Santa Ana - United States, Tustin - United States, Doral - United States, Fort Lauderdale - United States, Hialeah - United States, Hialeah - United States, Hialeah - United States, Miami Lakes - United States, Miami - United States, Miami - United States, Miami - United States, Miami - United States, Miami - United States, Miami - United States, Miami - United States, Miami - United States, Miami - United States, Miami - United States, Miami - United States, Miami - United States, Miami - United States, Miramar - United States, Saint Petersburg - United States, Skokie - United States, South Bend - United States, Lake Charles - United States, Auburn Hills - United States, Bay City - United States, Saint Joseph - United States, Parsippany - United States, New York - United States, New York - United States, New York - United States, Stony Brook - United States, Charlotte - United States, Charlotte - United States, Bexley - United States, Dublin - United States, Dublin - United States, Portland - United States, Columbia - United States, Greenville - United States, Murfreesboro - United States, Houston - United States, Pflugerville - United States, Pflugerville - United States, Sugar Land - United States, Sugar Land - United States, Sugar Land - United States, Springville - United States, Lynchburg - United States, Norfolk - United States, Sofia - Bulgaria, Winnipeg - Canada, Barrie - Canada, London - Canada, Oakville - Canada, Sudbury - Canada, Sudbury - Canada, Toronto - Canada, Montréal - Canada, Sherbrooke - Canada, Sherbrooke - Canada, Saskatoon - Canada, Quebec - Canada, Quebec - Canada, Beijing - China, Beijing - China, Beijing - China, Fuzhou - China, Guangzhou - China, Guangzhou - China, Guiyang - China, Shijiazhuang - China, Shijiazhuang - China, Nanyang - China, Wuhan - China, Baotou - China, Nanjing - China, Changchun - China, Changchun - China, Xi'an - China, Shanghai - China, Chengdu - China, Tianjin - China, Kunming - China, Hangzhou - China, Hangzhou - China, Fuzhou - China, Shanghai - China, Shijiazhuang - China, Mainz - Germany, Magdeburg - Germany, Magdeburg - Germany, Magdeburg - Germany, Pécs - Hungary, Gyula - Hungary, Szeged - Hungary, Szolnok - Hungary, Budapest - Hungary, Debrecen - Hungary, Debrecen - Hungary, Debrecen - Hungary, Kaposvár - Hungary, Nagoya - Japan, Nagoya - Japan, Sakura - Japan, Urayasu - Japan, Takarazuka - Japan, Inashiki-gun - Japan, Inashiki - Japan, Ikoma City - Japan, Habikino - Japan, Hamamatsu-shi - Japan, Hamamatsu - Japan, Bunkyō - Japan, Ube - Japan, Wroclaw - Poland, Bydgoszcz - Poland, Warszawa - Poland, Warszawa - Poland, Warszaw - Poland, Kraków - Poland, Bialystok - Poland, Bialystok - Poland, Lodz - Poland, Skierniewice - Poland, Katowice - Poland, Svidnik - Slovakia, Trnava - Slovakia, Bratislava - Slovakia, Bratislava - Slovakia, Kosice - Slovakia, Kosice - Slovakia, Barcelona - Spain, Madrid - Spain, Madrid - Spain, Madrid - Spain, Madrid - Spain, València - Spain, Zaragoza - Spain, Kaohsiung - Taiwan, Taipei - Taiwan, Taipei - Taiwan",2027-07-14,2023-10-10,2024-06-26,INTERVENTIONAL,PHASE3
NCT05636293,Ritlecitinib,"Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib to Prevent Gluten-induced Celiac Enteropathy and Symptoms in Celiac Disease Patients in Remission",Massachusetts General Hospital,Unknown,RECRUITING,30,2023-03-01,Celiac Disease,"Ritlecitinib, Placebo, Gluten","Change in Small Intestinal Histology based on Vh:Cd ratio, Patient Reported Outcome Surveys (CeD PRO survey evaluation)","Serology, Changes in Small Intestinal Histology of intraepithelial lymphocytes (IELs)",Boston - United States,2025-08-01,2022-12-05,2024-02-28,INTERVENTIONAL,PHASE2
NCT05650333,Ritlecitinib,"AN INTERVENTIONAL PK, PD, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE PK AND PD OF MULTIPLE-DOSE RITLECITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA",Pfizer,Unknown,COMPLETED,15,2023-03-02,Alopecia Areata,Ritlecitinib 20 mg,"Area under the plasma concentration time profile over the dosing interval 24 hrs, at steady-state (AUC24) on Day 7","Maximum Observed Plasma Concentration (Cmax), Time to Reach Maximum Observed Plasma Concentration (Tmax), Apparent Oral Clearance (CL/F), Apparent Volume of Distribution (Vz/F), Terminal elimination Half-Life (t1/2), Change from baseline in interferon gamma, IP-10 and lymphocyte subsets (T cell, B cell, and NK cells), Incidence of treatment emergent adverse event (TEAE), Incidence of Treatment related AEs, Incidence of Serious AEs (SAEs), Incidence of AEs leading to discontinuation, Clinically significant abnormalities in vital signs, Clinically significant abnormalities in clinical laboratory values, For overall taste, percent of participants reporting likeability on the scale from 1-5 will be reported, For overall mouthfeel, percent of participants reporting how the medicine felt on the scale from 1-5 will be reported., For overall volume, percent of participants reporting likeability of the amount of medicine taken on the scale from 1-5 will be reported.","Encinitas - United States, Coral Gables - United States, Miami - United States, Indianapolis - United States, Albuquerque - United States, Albuquerque - United States, Tulsa - United States, Portland - United States, San Antonio - United States",2023-08-11,2022-12-14,2023-08-25,INTERVENTIONAL,PHASE1
NCT06369454,Ritlecitinib,"A PHASE 1, RANDOMIZED, OPEN-LABEL, 2-SEQUENCE, 3-PERIOD STUDY TO CHARACTERIZE THE GASTROINTESTINAL TRANSIT OF A MODIFIED-RELEASE CAPSULE FORMULATION UNDER FASTED AND FED CONDITIONS BY SINGLE LABEL GAMMA SCINTIGRAPHY IN HEALTHY MALE ADULT PARTICIPANTS",Pfizer,Unknown,ACTIVE_NOT_RECRUITING,6,2024-05-03,Healthy Volunteers,Ritlecitinib,"Site of capsule disintegration and MR microsphere dispersion, Gastric emptying time, Small intestine residence/transit time, Colon arrival time, Colon (ascending, transverse, descending) residence/transit time, Total transit time","Maximum plasma concentration (Cmax), Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf), Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast), Time for Cmax (Tmax), Terminal half-life (t1/2), Frequency of adverse events, Frequency of abnormal clinical laboratory tests, Frequency of abnormal vital signs, Frequency of abnormal 12-lead ECG",Lexington - United States,2024-08-02,2024-04-17,2024-06-27,INTERVENTIONAL,PHASE1
NCT06450366,MK-0616,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-0616 Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia",Merck Sharp & Dohme LLC,Unknown,NOT_YET_RECRUITING,300,2024-07-15,Hypercholesterolemia,"MK-0616, Ezetimibe, Bempedoic Acid, Placebo for MK-0616, Placebo for Ezetimibe, Placebo for Bempedoic Acid",Mean Percent Change from Baseline in LDL-C at Day 56,"Mean Percent Change from Baseline in Apolipoprotein B (ApoB) at Day 56, Mean Percent Change from Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Day 56, Percent Change from Baseline in Lipoprotein(a) Levels (Lp[a]), Percentage of Participants Who at Day 56 Have an LDL-C <70 mg/dL and ≥50% Reduction from Baseline, Percentage of Participants Who at Day 56 Have an LDL-C <55 mg/dL and ≥50% Reduction from Baseline, Number of Participants With ≥1 Adverse Event (AE), Number of Participants Discontinuing from Study Therapy Due to AE",No locations listed,2025-07-21,2024-06-10,2024-06-10,INTERVENTIONAL,PHASE3
NCT05934292,MK-0616,"An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of MK-0616 in Participants With Varying Degrees of Renal Impairment",Merck Sharp & Dohme LLC,Unknown,COMPLETED,33,2023-07-20,Hypercholesterolaemia,MK-0616,"Panels A, B, and D: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-0616: Period 1, Panel C: AUC0-inf of MK-0616: Periods 1 and 2, Panels A, B and D: AUC from Time 0 to Last Measurable Concentration (AUClast) of MK-0616: Period 1, Panel C: AUClast of MK-0616: Periods 1 and 2, Panels A, B and D: Maximum Plasma Concentration (Cmax) of MK-0616: Period 1, Panel C: Maximum Plasma Concentration (Cmax) of MK-0616: Periods 1 and 2, Panel A, B, and D: Time to Maximum Plasma Concentration (Tmax) of MK-0616: Period 1, Panel C: Time to Maximum Plasma Concentration (Tmax) of MK-0616: Periods 1 and 2, Panels A, B and D: Apparent Terminal Half-life (t1/2) of MK-0616: Period 1, Panel C: t1/2 of MK-0616: Periods 1 and 2, Panel A, B and D: Apparent Clearance (CL/F) of MK-0616: Period 1, Panel C: Apparent Clearance (CL/F) of MK-0616: Periods 1 and 2, Panels A, B and D: Apparent Volume of Distribution (Vz/F) of MK-0616, Panel C: Apparent Volume of Distribution (Vz/F) of MK-0616","Dialysate Clearance (CLd) of MK-0616, Dialysate Concentration of MK-0616, Amount of MK-0616 Excreted (AEd) in Dialysate, Percentage of Dose (%Dose) of MK-0616 Excreted in Dialysate, Amount of MK-0616 Excreted in Urine from 0 to 24 hours (AE0-24), Fraction of Unchanged MK-0616 Excreted in Urine (Fe), Renal Clearance (CLr) of MK-0616, Percentage of Participants Who Experience at Least 1 Adverse Event (AE), Percentage of Participants Who Discontinue From the Study due to an AE","Hallandale Beach - United States, Miami - United States, Miami - United States, Orlando - United States, Tampa - United States",2024-01-19,2023-07-06,2024-02-07,INTERVENTIONAL,PHASE1
NCT05261126,MK-0616,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia",Merck Sharp & Dohme LLC,Unknown,COMPLETED,381,2022-03-10,"Hypercholesterolemia, Familial Hypercholesterolemia","MK-0616, Placebo","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 8, Percentage of Participants Who Experienced One or More Adverse Events (AEs), Percentage of Participants Who Discontinued Study Intervention Due to AEs","Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 8, Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 8, Percentage of Participants With LDL-C Value at Goal at Week 8","Beverly Hills - United States, Sacramento - United States, Santa Ana - United States, Boca Raton - United States, Coral Gables - United States, Tampa - United States, Flossmoor - United States, Indianapolis - United States, Topeka - United States, Louisville - United States, Jackson - United States, Las Vegas - United States, Albuquerque - United States, New Windsor - United States, Duncansville - United States, Fort Mill - United States, Dallas - United States, Houston - United States, San Antonio - United States, Richmond - United States, München - Germany, Nuremberg - Germany, Kassel - Germany, Leipzig - Germany, Berlin - Germany, Nagoya - Japan, Kuse-gun Kumiyama-cho - Japan, Osaka-city - Japan, Suita-shi - Japan, Adachi-ku - Japan, Chiyoda-ku - Japan, Shinjuku-ku - Japan, Toshimaku - Japan, Daegu - Korea, Republic of, Seoul - Korea, Republic of, Seoul - Korea, Republic of, Seoul - Korea, Republic of, Ciudad de México - Mexico, Mexico City - Mexico, Mexico City - Mexico, Guadalajara - Mexico, Guadalajara - Mexico, Monterrey - Mexico, Ciudad Madero - Mexico, Xalapa - Mexico, Merida - Mexico, Aguascalientes - Mexico, Lørenskog - Norway, Bodø - Norway, Stavanger - Norway, Tønsberg - Norway, Oslo - Norway, Oslo - Norway, Oslo - Norway, Oslo - Norway, Bornova - Turkey, Ankara - Turkey, Eskisehir - Turkey, London - United Kingdom, Glasgow - United Kingdom, Blackpool - United Kingdom, London - United Kingdom, West Midlands - United Kingdom",2022-11-28,2022-03-02,2023-12-06,INTERVENTIONAL,PHASE2
NCT05070390,MK-0616,An Open-Label Clinical Study to Evaluate the Pharmacokinetics of MK-0616 Following Administration of a Single Dose to Participants With Moderate Renal Impairment,Merck Sharp & Dohme LLC,Unknown,COMPLETED,18,2021-11-16,Moderate Renal Impairment,MK-0616,"Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-0616, AUC from Time 0 to Last Measurable Concentration (AUClast) of MK-0616, Maximum Plasma Concentration (Cmax) of MK-0616, Time to Maximum Plasma Concentration (Tmax) of MK-0616, Apparent Terminal Half-life (t1/2) of MK-0616, Apparent Clearance (CL/F) of MK-0616, Apparent Volume of Distribution (Vz/F) of MK-0616","Number of Participants Experiencing an Adverse Event (AE), Number of Participants Who Discontinue From the Study due to an AE, Amount Recovered in Urine from 0 to 24 hours (Ae0-24) of MK-0616, Fraction of Dose Recovered in Urine (Fe) of MK-0616, Renal Clearance (CLr) of MK-0616, Maximum Percent Change in Free Proprotein Convertase Subtilisin Kexin 9 (PCSK9) from Baseline","Hallandale Beach - United States, Knoxville - United States",2023-05-03,2021-10-07,2023-05-23,INTERVENTIONAL,PHASE1
NCT05952869,MK-0616,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia",Merck Sharp & Dohme LLC,Unknown,ACTIVE_NOT_RECRUITING,270,2023-08-08,"Hypercholesterolemia, Familial Hypercholesterolemia","MK-0616, Placebo","Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24, Number of participants with one or more adverse events (AEs), Number of participants who discontinue study drug due to an AE","Mean percent change from baseline in LDL-C at Week 52, Mean percent change from baseline in non-high-density lipoprotein cholesterol (HDL-C) at Week 24, Mean percent change from baseline in apolipoprotein B (ApoB) at Week 24, Percent change from baseline in lipoprotein(a) (Lp[a]) at Week 24, Percentage of participants with LDL-C <70 mg/dL and ≥50% reduction from baseline at Week 24, Percentage of participants with LDL-C <55 mg/dL and ≥50% reduction from baseline at Week 24","Daphne - United States, Boca Raton - United States, Cutler Bay - United States, Port Orange - United States, Winter Park - United States, Evansville - United States, Indianapolis - United States, Troy - United States, Lincoln - United States, Las Vegas - United States, Winston-Salem - United States, West Jordan - United States, Newport News - United States, Camperdown - Australia, Clayton - Australia, Fortaleza - Brazil, São Paulo - Brazil, Sao Paulo - Brazil, Chicoutimi - Canada, Montreal - Canada, Trois-Rivieres - Canada, Valdivia - Chile, Providencia - Chile, Santiago - Chile, Santiago - Chile, Medellín - Colombia, Barranquilla - Colombia, Barranquilla - Colombia, Bogotá - Colombia, Brno - Czechia, Brno - Czechia, Praha - Czechia, Helsinki - Finland, Pok Fu Lam - Hong Kong, Shatin - Hong Kong, Szeged - Hungary, Budapest - Hungary, Debrecen - Hungary, Jerusalem - Israel, Jerusalem - Israel, Petah Tikva - Israel, Sakhnin - Israel, Nijmegen - Netherlands, Amsterdam - Netherlands, Hoorn - Netherlands, Utrecht - Netherlands, Rotorua - New Zealand, Christchurch - New Zealand, Bodø - Norway, Oslo - Norway, Singapore - Singapore, Singapore - Singapore, Sant Joan Despí - Spain, Reus - Spain, Valencia - Spain, New Taipei City - Taiwan, Taipei City - Taiwan, Tainan - Taiwan, Taipei - Taiwan",2025-04-28,2023-07-19,2024-03-13,INTERVENTIONAL,PHASE3
NCT05952856,MK-0616,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia",Merck Sharp & Dohme LLC,Unknown,ACTIVE_NOT_RECRUITING,2760,2023-08-10,"Hypercholesterolemia, Familial Hypercholesterolemia","MK-0616, Placebo","Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24, Number of participants with one or more adverse events (AEs), Number of participants who discontinue study drug due to an AE","Mean percent change from baseline in LDL-C at Week 52, Mean percent change from baseline in non-high-density lipoprotein cholesterol (non-HDL-C) at Week 24, Mean percent change from baseline in apolipoprotein B (ApoB) at Week 24, Percent change from baseline in lipoprotein(a) (Lp[a]) at Week 24, Percentage of participants with LDL-C <70 mg/dL and ≥50% reduction from baseline at Week 24, Percentage of participants with LDL-C <55 mg/dL and ≥50% reduction from baseline at Week 24","Daphne - United States, Foley - United States, Phoenix - United States, Banning - United States, Beverly Hills - United States, Sacramento - United States, Washington - United States, Boca Raton - United States, Coral Gables - United States, Fort Myers - United States, Hallandale Beach - United States, Jacksonville - United States, Miramar - United States, Tampa - United States, Macon - United States, Flossmoor - United States, Evansville - United States, Indianapolis - United States, Lexington - United States, Louisville - United States, Slidell - United States, Rockville - United States, Gulfport - United States, Hazelwood - United States, Las Vegas - United States, Las Vegas - United States, Albuquerque - United States, East Syracuse - United States, New York - United States, Fargo - United States, Duncansville - United States, Yardley - United States, Fort Mill - United States, Greenville - United States, North Charleston - United States, Rapid City - United States, Kingsport - United States, Knoxville - United States, Dallas - United States, Houston - United States, San Antonio - United States, Salt Lake City - United States, West Jordan - United States, Manassas - United States, Newport News - United States, Norfolk - United States, Richmond - United States, Suffolk - United States, Renton - United States, Caba - Argentina, Ciudad Autónoma de Buenos Aires - Argentina, Mar del Plata - Argentina, Zárate - Argentina, Ciudad Autonoma de Buenos Aires - Argentina, Buenos Aires - Argentina, Beijing - China, Beijing - China, Chongqing - China, Chongqing - China, Guangzhou - China, Guangzhou - China, Huizhou - China, Shenzhen - China, Jingzhou - China, Wuhan - China, ChangSha - China, Changzhou - China, Yangzhou - China, Nanchang - China, Siping - China, Xianyang - China, Chengdu - China, Lishui - China, Medellín - Colombia, Barranquilla - Colombia, Barranquilla - Colombia, Bogotá - Colombia, Zipaquira - Colombia, Cali - Colombia, Essen - Germany, Hohenmölsen - Germany, Dresden - Germany, Bad Berka - Germany, Berlin - Germany, Berlin - Germany, Hadera - Israel, Haifa - Israel, Jerusalem - Israel, Jerusalem - Israel, Jerusalem - Israel, Kfar Saba - Israel, Petah Tikva - Israel, Ramat Gan - Israel, Zerifin - Israel, Rome - Italy, Milan - Italy, Milan - Italy, Torino - Italy, Rome - Italy, Catania - Italy, Kitakyusyu-shi - Japan, Naka - Japan, Ushiku - Japan, Kanazawa - Japan, Morioka - Japan, Sendai - Japan, Izumisano - Japan, Kashiwara - Japan, Suita-shi - Japan, Iruma - Japan, Bunkyo-ku - Japan, Chuo-ku - Japan, Chuo-ku - Japan, Itabashi-ku - Japan, Katsushika-ku - Japan, Mitaka - Japan, Nerima-ku - Japan, Ota-ku - Japan, Shinjuku-ku - Japan, Shinjuku-ku - Japan, Fukuoka - Japan, Hiroshima - Japan, Tokyo - Japan, Cheongju-si - Korea, Republic of, Wonju - Korea, Republic of, Gwangju-si - Korea, Republic of, Seongnam - Korea, Republic of, Suwon - Korea, Republic of, Busan - Korea, Republic of, Busan - Korea, Republic of, Haeundae-gu - Korea, Republic of, Daegu - Korea, Republic of, Seoul - Korea, Republic of, Seoul - Korea, Republic of, Seoul - Korea, Republic of, Seoul - Korea, Republic of, Seoul - Korea, Republic of, Seoul - Korea, Republic of, Cdmx - Mexico, Guadalajara - Mexico, Bloemfontein - South Africa, Johannesburg - South Africa, Johannesburg - South Africa, Bellville, Cape Town - South Africa, Cape Town - South Africa, Cape Town - South Africa, Sevilla - Spain, Centelles - Spain, A Coruña - Spain, Santiago de Compostela - Spain, Alcorcón - Spain, Pozuelo de Alarcón - Spain, Castilleja de la Cuesta - Spain, Valencia - Spain, Madrid - Spain, Changhua County - Taiwan, Kaohsiung Niao Sung Dist - Taiwan, Tainan City - Taiwan, Tainan - Taiwan, Taipei - Taiwan, Taipei - Taiwan, Taipei - Taiwan, Altindağ - Turkey, Bornova - Turkey, Ankara - Turkey, Eskisehir - Turkey, Kayseri - Turkey, Kocaeli - Turkey",2025-09-15,2023-07-19,2024-05-17,INTERVENTIONAL,PHASE3
NCT06008756,MK-0616,"Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk",Merck Sharp & Dohme LLC,Unknown,RECRUITING,14550,2023-10-09,"Arteriosclerosis, Hypercholesterolaemia","MK-0616, Placebo",Time to First Occurrence of Coronary Heart Disease (CHD) Death-Based Major Adverse Cardiovascular Events (MACE)-Plus,"Time to First Occurrence of 3-point MACE, Time to First Occurrence of Cardiovascular (CV) Death-Based MACE Plus, Time to First Occurrence of CHD Death or MI, Time to CV Death, Time to All-Cause Death, Time to CHD Death, Time to First Event of MI, Time to First Event of Ischemic Stroke, Time to First Event of Acute Limb Ischemia or Major Amputation, Time to First Event of Urgent Arterial Revascularization, Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C), Percent Change from Baseline in Apolipoprotein B, Percent Change from Baseline in Non-High-Density Lipoprotein Cholesterol (non-HDL-C) cholesterol, Percent Change from Baseline in Lipoprotein (a), Number of Participants with an Adverse Event (AE), Number of Participants Discontinuing from Study Therapy Due to AE","Alexander City - United States, Birmingham - United States, Birmingham - United States, Daphne - United States, Foley - United States, Phoenix - United States, Beverly Hills - United States, La Jolla - United States, Lancaster - United States, Los Angeles - United States, Pasadena - United States, San Mateo - United States, Tarzana - United States, Toluca Lake - United States, Torrance - United States, Aurora - United States, Littleton - United States, Stamford - United States, Waterbury - United States, Washington - United States, Boca Raton - United States, Cutler Bay - United States, Fort Myers - United States, Jacksonville - United States, Jacksonville - United States, Jacksonville - United States, Jacksonville - United States, Lake City - United States, Miami Lakes - United States, Miami - United States, Miramar - United States, Ocala - United States, Port Orange - United States, Saint Augustine - United States, Winter Park - United States, Macon - United States, Woodstock - United States, Chicago - United States, Chicago - United States, Flossmoor - United States, Gurnee - United States, Evansville - United States, Fort Wayne - United States, Indianapolis - United States, Kansas City - United States, Topeka - United States, Wichita - United States, Lexington - United States, Louisville - United States, Crowley - United States, Monroe - United States, Bangor - United States, Boston - United States, Boston - United States, Dearborn - United States, Grand Rapids - United States, Troy - United States, Maplewood - United States, Gulfport - United States, Tupelo - United States, Hazelwood - United States, Kansas City - United States, Elkhorn - United States, Lincoln - United States, Las Vegas - United States, Las Vegas - United States, Bridgewater - United States, Washington Township - United States, Albuquerque - United States, Binghamton - United States, Manlius - United States, New Hyde Park - United States, New Windsor - United States, New York - United States, Rochester - United States, Rosedale - United States, Winston-Salem - United States, Fargo - United States, Cincinnati - United States, Dayton - United States, Zanesville - United States, Oklahoma City - United States, Camp Hill - United States, Yardley - United States, Anderson - United States, North Charleston - United States, Rapid City - United States, Bristol - United States, Kingsport - United States, Knoxville - United States, Houston - United States, Odessa - United States, Pearland - United States, San Antonio - United States, San Antonio - United States, Sugar Land - United States, Tomball - United States, Salt Lake City - United States, Salt Lake City - United States, West Jordan - United States, Burke - United States, Charlottesville - United States, Falls Church - United States, Manassas - United States, Manassas - United States, Newport News - United States, Norfolk - United States, Suffolk - United States, Caba - Argentina, Ciudad Autónoma de Buenos Aires - Argentina, La Plata - Argentina, Lanus - Argentina, Mar del Plata - Argentina, Ramos Mejía - Argentina, San Nicolas - Argentina, Zárate - Argentina, Buenos Aires - Argentina, Buenos Aires - Argentina, Buenos Aires - Argentina, Ciudad Autonoma de Buenos Aires - Argentina, Córdoba - Argentina, Rosario - Argentina, Rosario - Argentina, Rosario - Argentina, Buenos Aires - Argentina, Santa Fe - Argentina, Santa Fe - Argentina, Bruce - Australia, Blacktown - Australia, Camperdown - Australia, Kanwal - Australia, Clayton - Australia, Fortaleza - Brazil, Brasilia - Brazil, Goiania - Brazil, Campina Grande do Sul - Brazil, Campo Largo - Brazil, Canoas - Brazil, Porto Alegre - Brazil, Porto Alegre - Brazil, Porto Alegre - Brazil, Bragança Paulista - Brazil, Campinas - Brazil, São José do Rio Preto - Brazil, São Paulo - Brazil, São Paulo - Brazil, Votuporanga - Brazil, Aracaju - Brazil, Rio de Janeiro - Brazil, Kelowna - Canada, Cambridge - Canada, North York - Canada, Oakville - Canada, Toronto - Canada, Chicoutimi - Canada, Montreal - Canada, Terrebonne - Canada, Trois-Rivieres - Canada, Temuco - Chile, Valdivia - Chile, Talca - Chile, Providencia - Chile, Santiago - Chile, Santiago - Chile, Santiago - Chile, Santiago - Chile, Santiago - Chile, Santiago - Chile, Ñuñoa - Chile, Viña del Mar - Chile, Hefei - China, Beijing - China, Beijing - China, Chongqing - China, Chongqing - China, Foshan - China, Guangzhou - China, Guangzhou - China, Huizhou - China, Jiangmen - China, Shenzhen - China, Guiyang - China, Haikou - China, Daqing - China, Harbin - China, Qiqihar - China, Nanyang - China, Wuhan - China, Changsha - China, Changsha - China, Changsha - China, Yueyang - China, Bao Tou - China, Chifeng - China, Hohhot - China, Changzhou - China, Nanjing - China, Yangzhou - China, Zhenjiang - China, Nanchang - China, Pingxiang - China, Changchun - China, Siping - China, Shenyang - China, Yinchuan - China, Taiyuan - China, Xi'an - China, Xianyang - China, Xian - China, Linyi - China, Zibo - China, Shanghai - China, Shanghai - China, Shanghai - China, Chengdu - China, Chengdu - China, Neijiang - China, Suining - China, Tianjin - China, Linhai - China, Lishui City - China, Medellín - Colombia, Medellín - Colombia, Medellín - Colombia, Barranquilla - Colombia, Barranquilla - Colombia, Barranquilla - Colombia, Manizales - Colombia, Valledupar - Colombia, Montería - Colombia, Bogota - Colombia, Bogotá - Colombia, Bogotá - Colombia, Bogotá - Colombia, Zipaquira - Colombia, Piedecuesta - Colombia, Ibague - Colombia, Cali - Colombia, Cali - Colombia, Gandrup - Denmark, Hjorring - Denmark, Slagelse - Denmark, Svendborg - Denmark, Hksar - Hong Kong, Pok Fu Lam - Hong Kong, Shatin - Hong Kong, Shatin - Hong Kong, Debrecen - Hungary, Nyíregyháza, Borbánya - Hungary, Budapest - Hungary, Debrecen - Hungary, Zalaegerszeg - Hungary, Ashkelon - Israel, Be'er Sheva - Israel, Hadera - Israel, Haifa - Israel, Haifa - Israel, Haifa - Israel, Herzliya - Israel, Holon - Israel, Jerusalem - Israel, Jerusalem - Israel, Jerusalem - Israel, Petah Tikva - Israel, Petah Tikva - Israel, Ramat Gan - Israel, Sakhnin - Israel, Nagoya - Japan, Nagoya - Japan, Matsudo - Japan, Itoshima - Japan, Kasuga - Japan, Nakagawa - Japan, Himeji - Japan, Tsukuba - Japan, Takamatsu-shi - Japan, Takamatsu - Japan, Fujisawa - Japan, Kamakura - Japan, Kuse-gun Kumiyama-cho - Japan, Uji - Japan, Ōmura - Japan, Saga-shi - Japan, Hanyu - Japan, Akishima - Japan, Hachioji - Japan, Higashiyamato-shi - Japan, Fukuoka - Japan, Fukuoka - Japan, Fukuoka - Japan, Kumamoto - Japan, Kyoto - Japan, Nagasaki - Japan, Okayama - Japan, Osaka - Japan, Saitama - Japan, Saitama - Japan, Tokyo - Japan, Seongnam - Korea, Republic of, Suwon - Korea, Republic of, Daegu - Korea, Republic of, Seoul - Korea, Republic of, Seoul - Korea, Republic of, Seoul - Korea, Republic of, Seoul - Korea, Republic of, Seoul - Korea, Republic of, Ciudad de México - Mexico, Mexico City - Mexico, Mexico City - Mexico, Guadalajara - Mexico, Guadalajara - Mexico, Zapopan - Mexico, Monterrey - Mexico, Monterrey - Mexico, Ciudad Madero - Mexico, Merida - Mexico, Aguascalientes - Mexico, Aguascalientes - Mexico, Aguascalientes - Mexico, Chihuahua - Mexico, Veracruz - Mexico, Veracruz - Mexico, Rotterdam - Netherlands, Hoogeveen - Netherlands, Sneek - Netherlands, Apeldoorn - Netherlands, Harderwijk - Netherlands, Nijmegen - Netherlands, Tiel - Netherlands, Zutphen - Netherlands, Venlo - Netherlands, Roosendaal - Netherlands, Amstelveen - Netherlands, Amsterdam - Netherlands, Amsterdam - Netherlands, Amersfoort - Netherlands, Goes - Netherlands, Dordrecht - Netherlands, Gouda - Netherlands, Leiderdorp - Netherlands, Rotorua - New Zealand, Tauranga - New Zealand, Christchurch - New Zealand, Christchurch - New Zealand, Palmerston North - New Zealand, Nawton - New Zealand, Ebdentown - New Zealand, Auckland - New Zealand, Auckland - New Zealand, Nelson - New Zealand, Lørenskog - Norway, Bergen - Norway, Bodø - Norway, Oslo - Norway, Oslo - Norway, Oslo - Norway, Arequipa - Peru, Trujillo - Peru, Miraflores - Peru, Lima - Peru, Lima - Peru, Lima - Peru, Lima - Peru, Lima - Peru, Lima - Peru, Piura - Peru, Piura - Peru, Port Elizabeth - South Africa, Bloemfontein - South Africa, Johannesburg - South Africa, Johannesburg - South Africa, Midrand - South Africa, Moloto - South Africa, Pretoria West - South Africa, Pretoria - South Africa, Bellville, Cape Town - South Africa, Cape Town - South Africa, Cape Town - South Africa, George - South Africa, Paarl - South Africa, Paarl - South Africa, Worcester - South Africa, Malaga - Spain, Sevilla - Spain, Barcelona - Spain, Santiago de Compostela - Spain, Alcorcón - Spain, Madrid - Spain, Madrid - Spain, Majadahonda - Spain, Pozuelo de Alarcón - Spain, El Palmar, Murcia - Spain, Castilleja de la Cuesta - Spain, Changhua County - Taiwan, Kaohsiung Niao Sung Dist - Taiwan, New Taipei City - Taiwan, Tainan City - Taiwan, Taichung - Taiwan, Taipei - Taiwan, Taipei - Taiwan, Taipei - Taiwan, Altindağ - Turkey, Bornova - Turkey, Karsiyaka - Turkey, Melikgazi - Turkey, Ankara - Turkey, Antalya - Turkey, Edirne - Turkey, Eskisehir - Turkey, Kocaeli - Turkey, Konya - Turkey, Bristol - United Kingdom, Exeter - United Kingdom, London - United Kingdom, Clydebank - United Kingdom, Corby - United Kingdom, Manchester - United Kingdom, Newcastle upon Tyne - United Kingdom, Sheffield - United Kingdom, Walsall - United Kingdom",2029-11-29,2023-08-24,2024-06-21,INTERVENTIONAL,PHASE3
